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ABSTRACT 
 
EX VIVO GENE THERAPY FOR LYSOSOMAL STORAGE DISEASE USING IPSC-DERIVED 
NEURAL STEM CELLS 
 
Tagan Aaron Griffin 
John H. Wolfe, V.M.D., Ph.D. 
 
Diseases affecting the central nervous system (CNS) pose a formidable obstacle to the delivery 
of effective therapeutics.  A tight-knit collection of cells and macromolecules known as the blood-
brain-barrier (BBB) prevents most substances from entering the brain.  One intriguing approach 
to overcoming this obstacle involves transplanting neural stem cells (NSCs), the precursor cells to 
neurons and glia in the brain, as vehicles for the delivery of therapeutic proteins in their native 
environment.  Notably, this strategy has already been successfully applied to several lysosomal 
storage diseases caused by genetic deficiencies in one of the many lysosomal hydrolases 
expressed throughout the body.  A major drawback to this approach is that foreign NSCs, e.g. 
immortalized cell lines and primary fetal NSCs can be tumorigenic and immunogenic.  Recently 
developed induced pluripotent stem cell (iPSC) technologies, combined with pluripotent stem cell 
differentiation techniques, have the potential to overcome these obstacles.  This approach was 
evaluated using a comprehensive strategy targeting a prototypical lysosomal storage disease, Sly 
disease (MPS VII).  MPS VII patient fibroblasts were transduced with retroviral vectors expressing 
the transcription factors Oct4, Sox2, Klf4, and c-Myc.  Patient fibroblasts were reprogrammed into 
embryonic stem cell-like iPSCs that demonstrated hallmarks of pluripotency.  Patient iPSCs, 
alongside iPSCs derived from an unaffected individual, were subjected to a stepwise 
differentiation protocol, yielding a relatively homogenous population of NSCs.  Following in vitro 
characterization, patient iPSCs were genetically corrected using a DNA transposon-based vector.  
Transplantation of NSCs into neonatal MPS VII mice revealed that these cells could migrate long 
distances and survive for several months.  However, corrected grafts expressing physiological 
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levels of the missing enzyme, β-glucuronidase, were too sparse to significantly ameliorate 
pathology.  In contrast, the same cells transplanted into the post-symptomatic adult MPS VII 
striatum were restricted to the injection site. Corrected, but not uncorrected patient iPSC-NSCs, 
were able to restore pathologically activated microglia to a normal quiescent state in a zone 
surrounding the graft. Together, these results provide evidence that ex vivo NSC gene therapy 
may be a viable option for many lysosomal storage diseases using easily attainable, non-neural 
patient tissue.   
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I. Lysosomal Storage Disease and Mucopolysaccharidosis 
Optimal cellular health requires a balance between the metabolism and catabolism of 
macromolecules within the cell.  In concert with the ubiquitin-proteasome system, the lysosome is 
responsible for the breakdown and recycling of macromolecules directly from the cytoplasm and 
via fusion with vesicles such as phagosomes, autophagosomes, and endosomes.  The discovery 
of the lysosome was a seminal event in the history of cell biology, winning Christian de Duve the 
Nobel Prize in Medicine or Physiology in 1974.  It is now increasingly recognized that the 
autophagosome-lysosome system acts as a central point of convergence for many cellular 
processes, reacting dynamically to the environment and contributing to overall cellular 
homeostasis (Behrends et al. 2010).  The lysosome consists of many soluble acid hydrolases 
(~50) along with dozens of membrane bound proteins (~25 discovered so far) responsible for 
trafficking, nutrient sensing, membrane fusion, cytoplasmic import/export, and generation of an 
immense pH gradient (Saftig et al. 2009). 
Loss-of-function mutations in lysosomal genes are responsible for many diseases related 
to defective catabolism within the cell, the lysosomal storage diseases (LSDs).  Individually, these 
diseases are rare, but as a group they represent one of the most common causes of monogenetic 
disease affecting humans today (~1:7500 live births) (Meikle et al. 2004).  The majority of LSDs 
are the result of genetic mutations that negatively impact the enzymatic function of a soluble 
lysosomal hydrolase.  Depending on which hydrolase is affected, the consequent accumulation of 
the primary substrate/s involved can result in myriad indirect pathologies which are incompletely 
understood (Walkley et al. 1998, Settembre et al. 2008, Ohmi et al. 2009). 
While many of the pathological cascades accompanying lysosomal dysfunction remain a 
mystery, there remains tremendous hope for treating soluble hydrolase deficiencies based on 
some of their unique physiological properties.  Lysosomal hydrolases are translated in the 
endoplasmic reticulum and processed in the golgi to include a terminal mannose-6-phosphate 
(M6P) moiety on specific asparagine residues (Brown et al. 1984).  M6P receptors concentrated 
in the cis-golgi direct bound enzymes through pre-lysosomal compartments towards the lysosome 
proper (Griffiths et al. 1988).  A minor fraction of M6P-tagged enzymes do not traffic to the 
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lysosome but rather escape the cell via endosomal fusion with the cell membrane. Now in the 
extracellular space, soluble enzymes can bind M6P receptors on the surface of neighboring cells, 
triggering endocytosis and trafficking towards the lysosome (Coutinho et al. 2012).  The sensitive 
pH dependence of lysosomal hydrolases (~4.5) prevents premature activation prior to reaching 
the lysosome. (Roederer et al. 1987).  Importantly, this pathway can be exploited to treat the 
majority of lysosomal storage diseases.   
Definitive evidence for the inter-cellular trafficking of lysosomal hydrolases came from a 
series of landmark studies, led by Elizabeth Neufeld’s lab, using mixed fibroblast cultures derived 
from two patients with different lysosomal sorage diseases.  The cells from both patients 
contained pathologically high levels of mucopolysaccharides (known today as 
glycosaminoglycans, or GAGs) (Fratantoni et al. 1968).  One patient had Hurler’s syndrome 
(MPS I), while the other had Hunter’s syndrome (MPS II).  The two diseases are clinically related 
and both phenotypes exhibit elevated levels of the GAGs heparan sulfate and dermatan sulfate 
throughout the body (Wraith 1995).  Remarkably, co-culturing MPS I and MPS II fibroblasts 
reduced the GAG burden in cells from both patients, a process now referred to as cross-
correction.  Neufeld’s group went on to demonstrate that the corrective factors were functional 
soluble hydrolases (α-L-iduronidase and iduronidate-2-sulfatase, respectively) absent in diseased 
cells (Fratantoni et al. 1968, Fratantoni et al. 1969). 
The mucopolysaccharidoses (MPSs) are an important group of LSDs caused by 
mutations affecting one of 11 enzymes responsible for the step-wise degradation of GAGs (Platt 
et al. 2004).  All but one of these diseases are autosomal recessive (MPS II is X-linked) (Berg et 
al. 1968). GAGs are a heterogenous group of linear polysaccharides broadly categorized into 
groups defined by one of the following component disaccharide units: heparin/heparan sulfate, 
chondroitin/dermatan sulfate, keratan sulfate, or hyaluronan. Depending on which enzyme is 
defective, patients can accumulate one or more classes of GAG (Esko et al. 2009). 
Since the early days of Neufeld’s pioneering studies, the MPSs have been studied 
extensively, yielding diverse insights into lysosome biogenesis, autophagy, intracellular 
trafficking, neuron dendritogenesis, and gene expression networks (Goodman et al. 1996, 
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McGlynn et al. 2004, Settembre et al. 2008, Cox et al. 2012).  MPS diseases are utilized not only 
for their contributions to basic cell biology, but also to evaluate novel treatment strategies, in part 
because of a well-understood therapeutic mechanism (the M6P pathway) and numerous animal 
models that recapitulate human LSDs.    
Enzyme replacement therapy (ERT) was first developed for Type I Gaucher disease, the 
most common LSD (Barton et al. 1990).  Unique among enzyme therapeutics, currently approved 
formulations of β-glucocerebrosidase for Gaucher disease are modified such that enzyme 
glycans terminate in mannose residues.  The rationale for this approach was to increase uptake 
in macrophages, preferentialy affected in Type I Gaucher disease, via the mannose receptor 
rather than the M6P receptor (Brady 2006).  Although the benefit of this particular approach is 
unproven, ERT is nevertheless effective in treating nonneuronopathic forms of Gaucher disease.   
ERT is now available for several LSDs including MPS I, MPSII, and MPS IVA.  However, there 
remains a fundamental obstacle to treating LSD pathology in the CNS: the blood-brain-barrier.  
Gaucher disease patients with the acute neuronopathic form of the disease (L444P) showed no 
improvement when treated with recombinant enzyme even very early in life (Prows et al. 1997).  
Most LSDs, including the MPSs, have some level of CNS involvement (Platt et al. 2004). 
While it has been reported that extremely high levels of IV recombinant enzyme 
(20/mg/kg/week) can have modest success in clearing storage lesions in the brains of MPS VII 
mice, it is clear that additional strategies are needed (Vogler et al. 2005).  Some groups have 
reported enzyme activity in the brain following bone marrow transplantation, presumably 
mediated by bone marrow derived cells entering the brain (Zheng et al. 2003, Zheng et al. 2004).  
However, success requires lethal irradiation or intense chemotherapy, creating a niche into which 
bone marrow derived monocytes can enter the brain to replace resident microglia (Morganti et al. 
2014).  It has since been demonstrated that the yolk-sac, and not the bone marrow, is the normal 
developmental origin of microglia and other tissue resident macrophages (Perdiguero et al. 
2014).  Microglia are normally self-renewing, they are replaced by bone marrow derived 
precursors at a very low rate under normal circumstances and when the brain is shielded during 
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whole-body irradiation (Derecki et al. 2012).  These studies demonstrate an unmet need for 
effective strategies targeting LSD pathogy in the CNS.    
 
II. Neuropathology of Mucopolysaccharidosis 
In order to develop effective CNS therapies, well characterized animal models are crucial.  
Naturally occurring and genetically modified animals with MPS have served as some of the best 
models for developing therapies targeting the CNS.  True homologues of human disease, MPS 
animal models have been extensively characterized (Levy et al. 1996, Haskins et al. 2002).  
Large animal models of MPS are particularly important for evaluating CNS-targeted therapies.  
When compared to mice, animals such as cats and dogs have very large brains, more accurately 
representing the challenge of achieving widespread enzyme delivery in humans (Wolfe et al. 
2000).  Local treatments that work well in mice, such as the injection of viral vectors encoding 
lysosomal enzymes, are generally ineffective when it comes to treating global CNS pathology in 
large animals and LSD patients (Heuer et al. 2002, Cearley et al. 2007, Ponder et al. 2007, 
Worgall et al. 2008). 
In order to effectively evaluate corrective therapies, it is important to understand the 
complicated pathological sequelae of primary substrate accumulation. As long lived non-dividing 
cells, neurons are particularly susceptible to the buildup of GAGs.  Consequently, MPS diseases 
often involve neurological impairment.  Patterns of neuropathology, common to a wide range of 
LSDs, provide insights into disease mechanisms and may help guide treatment strategies. 
While the primary feature of all MPSs is the intracellular accumulation of undegraded 
GAGs, there is a secondary accumulation of products for which GAG degrading enzymes are not 
required (Walkley 2004).  Primary GAG storage affects the expression and distribution of many 
lysosomal enzymes in MPS patients (Kint et al. 1973, Hollak et al. 1994).  The GAGs heparan 
sulfate and chondroitin sulfate can bind many lysosomal enzymes, decreasing their activity in 
vitro (Avila et al. 1975).  Interestingly, secondary storage products often do not co-localize with 
GAGs, implicating broader defects in endosomal sorting pathways (McGlynn et al. 2004). 
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The exact composition of secondary storage products depends on the particular disease.  
The brains of mice with MPS I, IIIA, IIIB, and VII were all found to accumulate the gangliosides 
GM2 and GM3 in varying amounts.  Cholesterol storage was shown in MPS I, IIIA, IIIB, but not in 
MPS VII (McGlynn et al. 2004).  Specific morphological alterations can be observed in cells 
accumulating certain primary or secondary storage products.  Alterations include the enlargement 
of axon hillocks (meganeurites) and the formation of ectopic dendrites, observed in cortical 
pyramidal neurons subsequent to GM2 accumulation (Walkley 2004).  Meganeurites are found in 
many LSDs including Tay-Sachs, α-mannosidosis, fucosidosis, Batten disease, Niemann-Pick 
type C, MPS I, and MPS VI. 
GM2 ganglioside is thought to be particularly important in the neuropathology of many 
LSDs.  Ectopic dendrites, often protruding from the meganeurite, are found exclusively in neurons 
accumulating GM2 ganglioside (Goodman et al. 1991).  High levels of GM2 ganglioside are not 
commonly seen in healthy mature neurons, but they are present in developing neurons 
undergoing normal dendritogenesis. One theory is that GM2 may be inappropriately activating 
dendritogenesis in susceptible neuronal subtypes, thus contributing to neurological dysfunction 
(Goodman et al. 1996). 
Another common feature of LSD neurons is the presence of axonal spheroids.  These 
large swellings, distal to the cell body, are common to a wide range of neurodegenerative 
diseases.  They contain a dense collection of autophagosomal-like and multivesicular-type bodies 
(Platt et al. 2004).  Axonal spheroids are most common in GABAergic neurons, especially 
purkinje cells in the cerebellum, which are particularly vulnerable to cell death in several LSDs 
(March et al. 1997).  A characteristic of MPS neurons are “zebra bodies”, so-called for their 
multilamellar striped appearance (Bhaumik et al. 1999).  
    Inflammation is a significant component of many LSDs, including MPS diseases.  
Gene expression profiling of the MPS VII mouse brain revealed that many inflammatory-related 
transcripts are significantly altered relative to unaffected littermate controls (Parente et al. 2012).  
There is evidence that GAGs may directly contribute to this pro-inflammatory state.  Heparan 
sulfate oligosaccharides can activate microglia in vitro via TLR4, and the extent of microglial 
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activation correlates with disease progression in MPS mice (Ohmi et al. 2003, Ausseil et al. 
2008).  However, deletion of TLR4 or the adapter protein MyD88 did not decrease other markers 
of disease progression in MPS IIIB mice, indicating that microglial activation is not a major 
determinant of neurodegeneration in this disease (Ausseil et al. 2008).  Recently, an MPS 
VII/TLR4/complement component 3 (C3) (MPS VII-/-/TLR4-/-/C3-/-) mouse was reported, but the 
CNS phenotype was not described (Xing et al. 2015).  Neurological function and lifespan in mice 
with the LSD Sandhoff disease (GM2 gangliosidosis) are improved when crossed to mice lacking 
Macrophage-inflammatory protein 1 alpha (MIP-1α) (Wu et al. 2004).  GAGs can bind and 
enhance the acitivity of several pro-inflammatory cytokines, including MIP-1α (Ali et al. 2000).  
MPS IIIB mice have high levels of perforin and granzyme B transcripts in the brain, suggesting 
inappropriate NK or CD8 T cell activity (Villani et al. 2009).   
Autophagy is a process involving the selective and non-selective degradation of cytosolic 
proteins and entire organelles.  Autophagy becomes grossly dysregulated in many LSDs because 
lysosomal hydrolases are ultimately responsible for much of the actual degradation following 
autophagosome-lysosome fusion (Settembre et al. 2008).  Mutant mice lacking key autophagic 
proteins gradually accumulate undegraded proteins within large poly-ubiquitinated inclusions, 
leading to cell death and severe neurodegeneration (Komatsu et al. 2006).  Interestingly, poly-
ubiquitinated inclusions and other hallmarks of defective autophagy are common to many 
neurodegenerative diseases including dementia, Parkinson’s, Huntington’s, and Alzheimer’s 
(Damme et al. 2014).  All the evidence is consistent with a central role for autophagy in the 
neurodegenerative process, suggesting that insights gleaned from genetically tractable LSDs 
may also apply to more common, idiopathic forms of neurodegenerative disease. 
 Autophagy and lysosomal biogenesis are tightly regulated at the transcriptional level by 
the transcription factor TFEB (Sardiello et al. 2009).  mTORC1-dependent phosphorylation of 
TFEB results in cytoplasmic sequestration, whereas dephosphorylated TFEB translocates to the 
nucleus, greatly enhancing lysosome biogenesis (Roczniak-Ferguson et al. 2012, Settembre et 
al. 2012).  The coordinated action of TFEB, a master regulator of lysosomal gene expression, 
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may explain why some pathological features (e.g., secondary enzyme elevation) are common to 
many or all LSDs.   
Much of the data regarding neuropathology in the MPS VII mouse brain comes from 
electron microscopy and immunohistochemical studies (Levy et al. 1996, Heuer et al. 2002).  
Electron micrographs show that lysosomal storage is established by three weeks of age and 
gradually increases thereafter.  Storage is distributed uniformly in most non-neuronal cells, and 
varies among neurons depending on subtype and location.  Neurons in the CA2, CA3, and CA4 
regions of the hippocampus are heavily distended by cytoplasmic vesicles whereas neurons in 
CA1 appear relatively unaffected.  Brain regions with a high storage burden correspond to regions 
of weak β-glucuronidase activity in normal mice (Levy et al. 1996).  Immunohistochemical 
staining showed a significant difference in the number of ubiquitin-positive inclusions in MPS VII 
and normal mice at 3 months of age (Heuer et al. 2002).  By 5 months, additional markers of 
neuropathology are present including neurofilament inclusions, Fluoro-Jade positive cells, and 
astrogliosis.  Following administration of an adeno-associated viral (AAV) vector expressing β-
glucuronidase, markers of neuropathology were restored to normal levels in the transduced 
region (Heuer et al. 2002).  Currently, viral vectors are limited in their ability to transduce cells 
throughout the brain.  This limitation might be overcome, perhaps in the near future, through a 
strategic choice of vector serotypes and optimized routes of administration (Cearley et al. 2008, 
Hinderer et al. 2014). 
Another promising approach to achieving widespread enzyme delivery throughout the 
brain is neural stem cell (NSC) transplantation.  Over 20 years ago, a mouse NSC line was 
shown to migrate widely and secrete therapeutic levels of β-glucuronidase in MPS VII mice 
(Snyder et al. 1995).  Since that time, key discoveries have made it possible to derive NSCs from 
easily accessible patient tissue, but ex vivo gene therapy using this approach has yet to be 
demonstrated. 
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III. Induced Pluripotent Stem Cells 
Experiments by Briggs and King in the 1950s demonstrated that nuclei from frog 
blastocysts could be transferred to enucleated oocytes, giving rise to a healthy adult frogs (Briggs 
et al. 1952).  John Gurdon later showed that nuclei from fully differentiated skin cells could 
accomplish the same feat (Gurdon et al. 1975).  The clear implication of these studies was that 
nuclei removed from fully differentiated cells retained the epigenetic plasticity necessary to derive 
the entire embryo.  Dolly the sheep famously demonstrated that this phenomenon was not just a 
quirk of frog biology (Wilmut 2003).  Other milestones of reprogramming include the development 
of mouse and human embryonic stem cells (ESCs), derived from the inner cell mass of mice 
(Evans et al. 1981, Martin 1981) and men (Thomson et al. 1998). 
Less than a decade ago, Shinya Yamanaka demonstrated that retroviral expression of 4 
genes (the transcription factors Oct4, Sox2, Klf4, and c-Myc) was sufficient to reprogram somatic 
cells to a pluripotent state (Takahashi et al. 2006).  When these induced pluripotent stem cells 
(iPSCs) were transplanted into a mouse blastocyst they were capable of forming chimeras and 
contributing to every cell type in an adult mouse, including germ cells (Wernig et al. 2007).  
Shortly thereafter, this same strategy was successfully applied to human cells using the same set 
of factors (Takahashi et al. 2007) or a different set (Oct4, Sox2, Nanog, and Lin28) (Yu et al. 
2007). With these developments, the field of transcription factor-based nuclear reprogramming 
was born. 
iPSCs can be generated using relatively simple procedures, leading to the rapid adoption 
of this technology as a means to study embryogenesis, create in vitro models of disease, and 
develop novel stem cell therapeutics.  For extensive reviews on the rapid advances following 
Yamanaka’s original discovery, see (Robinton et al. 2012) and (Stadtfeld et al. 2010).  There has 
been debate over exactly how faithful these iPSCs are to blastocyst-derived ESCs, with some 
groups showing that the cell-of-origin biases iPSC gene expression, leaving behind an 
“epigenetic memory” (Mikkelsen et al. 2008, Kim et al. 2010, Sullivan et al. 2010).  However, most 
of these studies used early passage iPSCs, and a preponderance of evidence has shown that 
iPSCs gradually lose this epigenetic memory over time. With sufficient passaging under the right 
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conditions and cultured in the same lab, iPSCs fall well within the normal variation of ESC lines in 
terms of DNA methylation status, histone modifications, and differentiation capacity (Bammler et 
al. 2005, Guenther et al. 2010), While some debate remains (Chin et al. 2010), iPSCs and ESCs 
can, for most practical purposes, be considered epigenetically and functionally equivalent (Smith 
et al. 2009, Zhao et al. 2009, Guenther et al. 2010). 
Most labs currently working with iPSCs have been interested in one of three primary 
areas of research: basic mechanisms of reprogramming and the epigenetic basis of cell fate, 
disease modeling using patient-derived iPSCs, and cell therapy using patient-derived iPSCs 
(Kanawaty et al. 2009, Okano et al. 2014, Theunissen et al. 2014).  The first labs to isolate iPSCs 
were focused on the mechanisms of how the pluripotent state arises and is maintained.  iPSCs 
are valuable tools for addressing these questions and much has been learned regarding the 
molecular mechanisms of reprogramming.  How exactly can so few TFs induce a genome-wide 
pluripotent state?  Can small molecules speed up the process or make it more efficient?  How 
closely related are pluripotent cells in vitro to their inner cell mass counterparts?  Can any 
differentiated cell type be converted directly into any other through the proper combination of TF 
overexpression?  Some of these questions have been answered using iPSC technology, and 
many questions remain (Hanna et al. 2010). 
Application of high-throughput sequencing techniques yields insights related to global 
transcriptional and epigenetic networks and how these change during reprogramming (Kim et al. 
2008, Ang et al. 2011). Studies comparing ESCs and blastocysts demonstrated that transcription 
factors involved in the reprogramming process, such as Oct4 and Nanog, are the same factors 
responsible for maintaining pluripotency in the early blastocyst (Marson et al. 2008).  Global 
reorganization of gene expression, histone status, and DNA methylation has been found to be a 
highly coordinated process.  Many factors are involved including polycomb repressor complexes 
(Boyer et al. 2006), DNA methyltransferases (Li et al. 2007, Deng et al. 2009), histone 
modification complexes (Lessard et al. 2010), microRNAs (Wang et al. 2013) and gene regulatory 
networks (Muraro et al. 2013).  Using techniques such as ChIPseq, high-throughput DNA and 
RNA sequencing, and high-throughput analysis of global DNA methylation and histone status in 
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ESCs and iPSCs, we understand much more about the pluripotent state and cell differentiation 
than we did only a decade ago (Robinton et al. 2012). 
Since the first derivation of human ESCs (Thomson et al. 1998), many labs have focused 
on developing protocols to generate specific cell types from pluripotent cells (Odorico et al. 2001).  
The advent of iPSC technology allows for the derivation of patient-specific cell types, useful for 
disease modeling and cell therapy, which would have been difficult or impossible to obtain 
otherwise. 
      
IV. Generating and Utilizing Neural Lineages from Pluripotent Stem Cells 
By the early 1990’s, methods were established for the identification of NSCs, as well as 
the culture conditions and growth factors required to isolate and maintain primary fetal and adult 
NSCs in vitro (Cattaneo et al. 1990, Reynolds et al. 1992, Kilpatrick et al. 1993, Davis et al. 1994, 
Palmer et al. 1995). Shortly thereafter, the first therapeutic studies were carried out, using the 
MPS VII mouse as a disease model (Snyder et al. 1995).  NSCs isolated from the cerebellum of 
neonatal mice, immortalized with the oncogene v-Myc (C17.2 cell line) (Ryder et al. 1990, Snyder 
et al. 1992), were successfully transplanted into the ventricles of neonatal MPS VII mice (Snyder 
et al. 1995). Not only did the cells survive but they migrated widely, delivering sufficient levels of 
the missing enzyme, β-glucuronidase (GUSB), to prevent storage lesions throughout the brain 
(Snyder et al. 1995).  Unfortunately, the use of immortalized cell lines for transplantation has clear 
disadvantages, namely the strong likelihood of tumorigenesis or immune rejection in the host.  
The MPS VII mouse has served as a useful model for developing new, more clinically relevant 
gene and cell therapies in the brain thanks to its well characterized pathology, sensitive and 
quantitative enzyme assays, and a viable mechanism for correcting every cell in the brain (cross-
correction) (Wolfe et al. 1990). 
Tissue isolated from fetal brains has been proposed as an alternate source of NSCs and 
several small trials have evaluated this strategy, with mostly disappointing results (Bjorklund et al. 
2000, Aboody et al. 2011, Thomsen et al. 2014).  A rare example of success was recently 
published following up 2 patients with Parkinson’s disease that had been injected with fetal 
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ventral mesencephalic tissue over 15 years ago.  Both patients showed moderate motor 
improvement over time and were able to discontinue dopaminergic therapy (Kefalopoulou et al. 
2014).  Many similar trials involving fetal grafts for Parkinson’s disease over the past 30 years 
have ended in failure, either because the grafted cells quickly took on the Parkinsonian 
phenotype of the surrounding cells (Kordower et al. 2008, Li et al. 2008) or because the grafted 
cells actually induced additional dyskinesias (Aboody et al. 2011, Lindvall 2013). 
Clearly there is not enough basic knowledge of NSCs, regarding their diversity and their 
interactions with diseased environments, to proceed with large-scale clinical trials.  More animal 
studies are needed to determine the optimal source of transplantable NSCs.  If the fetal brain is 
not an optimal source, than what is?  Pluripotent stem cells have the ability to differentiate into 
any cell type in the body, and can now be derived from a patient’s own cells, making them 
particularly attractive candidates for NSC therapy.  
Many protocols have been developed for the differentiation of pluripotent stem cells 
(primarily ESCs) into multipotent neural progenitors as well as mature neurons and glia.  While 
specific protocols come with advantages and disadvantages, they all rely on similar mechanisms 
to recapitulate early neural development (Lanza et al. 2004, Abranches et al. 2009).  Nearly every 
protocol that successfully induces neural lineage differentiation relies on a stepwise series of 
culture conditions, utilizing combinations of signaling molecules at specific dosages and time 
points to mimic in utero development.  Confirming their functionally similar nature, ESCs and 
iPSCs respond the same way to various neuralization protocols (Hu et al. 2010).   
Neuralization procedures first recapitulate early neurogenic signaling events involving 
molecules such as FGFs, Wnts, and BMPs (Wilson et al. 2001).  The first example of directed 
neural differentiation from ES cells comes from (Bain et al. 1995).  ESCs were detached from 
their mouse embryonic fibroblast (MEF) feeder layer to generate spherical aggregates, or 
“embryoid bodies” (EBs), which were then exposed to retinoic acid.  Many cells within the EBs 
differentiated into neuron-like cells characterized by the firing of action potentials and expression 
of tetrodotoxin (TTX)-sensitive sodium channels, voltage-gated potassium channels, and calcium 
channels (Bain et al. 1995).  Exposure to conditioned media from the HepG2 cell line also 
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increases the efficiency of EB conversion towards neural lineages (Rathjen et al. 2003).  EBs can 
be dissociated and grown as a monolayer of neural progenitors, which led to the co-culture of 
ESCs with various cells lines in an attempt to convert ESCs even more efficiently.  It was found 
that certain mouse stromal lines, e.g. PA6 (Kawasaki et al. 2000) or MS5 (Barberi et al. 2003), 
support neural differentiation from ESCs quite efficiently.  
A crucial refinement to the basic EB protocol by (Okabe et al. 1996) involved plating 4 
day-old EBs in fetal calf serum to promote attachment, followed by growth in a minimal neural 
induction media.  Further passaging of these cells in an optimized NSC media, plus the addition 
of cytosine arabinose to inhibit astrogliogenesis, yields relatively pure populations of 
transplantable NSCs (Okabe et al. 1996). 
One of the easiest and most efficient neural differentiation protocols is known as “dual 
SMAD inhibition” (Chambers et al. 2009), which involves the application of only two crucial 
morphogens (Noggin, an inhibitor of TGF-β proteins including BMP-4, and the small molecule 
SB431542, an inhibitor of several activin receptor-like kinases [AKTs]) (Lamb et al. 1993, Laping 
et al. 2002).  Following the application of these 2 morphogens, over 80% of ESC or iPSCs 
become PAX6+ early neural progenitor cells that can be further differentiated towards various 
mature neuronal subtypes (Chambers et al. 2009).   
Another important development in the generation of transplantable NSCs does not 
involve pluripotent cells at all.  Combinations of transcription factors were shown by several 
groups to directly generate neural progenitors, thus bypassing the pluripotent stage (Han et al. 
2012, Lujan et al. 2012, Sheng et al. 2012).  This method has several advantages, specifically a 
lower risk of tumorigenesis following transplantation, as well as the speed at which these cells 
can be generated and characterized. It remains to be seen how faithful these cells are to 
endogenous and pluripotent cell-derived NSCs, but so far the data seem promising (Lujan et al. 
2012).    
One particularly interesting feature of neural differentiation is that it seems to be the 
default pathway for differentiating pluripotent cells (Munoz-Sanjuan et al. 2002).  This indirectly 
led to the discovery that BMP-4 is the primary inhibitor of neural induction (Wilson et al. 1995).  If 
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human ESC cultures, in the absence of exogenous factors, remain in the same culture dish for 
several weeks, neural cells begin to emerge (Reubinoff et al. 2001).  The addition of FGF and 
EGF enhance this induction, allowing NSCs to be cultured as a relatively homogenous population 
expressing the neural markers nestin, vimentin, and PAX6 (Reubinoff et al. 2001). 
While there are differences in neurodevelopmental signaling pathways between mice and 
humans, they appear to be more alike than different (Moon et al. 2006).  Similar protocols yield 
remarkably similar results and human pluripotent stem cell-derived neural progenitors can 
functionally integrate into cortical circuits in mice, although this process can take several months 
(Espuny-Camacho et al. 2013).  One significant example of a species-specific difference is that 
Sox1 is the first neural-associated gene to be expressed in mice while Pax6 (expressed before 
Sox1) is both necessary and sufficient for neurectodermal formation in humans (Zhang et al. 
2010).      
There are several different protocols that give rise to early neural progenitors, but every 
method has drawbacks, depending on the application in question.  Most protocols generate 
neural lineages by recapitulating early neural development.  In doing so, they suffer the same fate 
as endogenous neural progenitors, demonstrating a shift from a neuronogenic to a gliogenic bias 
after many cell divisions, mimicking the situation seen in normal brain development (Abranches et 
al. 2009, Edri et al. 2015).  Several groups have tried to overcome this bias by selectively 
culturing cells at an early “rosette” stage of neural development, reminiscent of the early neural 
tube.  It has been shown that such cells can retain a broad and consistent differentiation potential 
over many passages (Elkabetz et al. 2008, Koch et al. 2009). 
 Large scale clinical application of ESC/iPSC-derived NSCs will require a level of 
consistency that is difficult to obtain using cells that change significantly with passage number.  It 
would require redifferentiating each batch of cells and extensively testing them for batch-to-batch 
variability.  So far, a protocol developed by Koch et al. is unique in that it produces cells that 
maintain a consistent gene expression profile and differentiation capacity over 100 passages at 
an NSC stage (Koch et al. 2009).  This method was developed using ESC lines but also works 
with iPSCs (Falk et al. 2012).  A protocol with similar properties may be ideal for transplantation 
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studies or future clinical use.  These “long-term self-renewing NSCs” do show a bias towards 
generating GABAergic neurons of the hindbrain upon passive withdrawal of growth factors, but 
the cells remained responsive to regionalization cues across time, generating both dopaminergic 
and motor neurons in appropriate culture conditions (Koch et al. 2009).  
 
V. Rationale 
We have devised and evaluated a comprehensive strategy for the treatment of lysosomal 
enzyme deficiencies in the brain involving the reprogramming, differentiation, and genetic 
correction of diseased somatic cells.  We chose MPS VII as a model system because it has been 
well characterized and for its long history as a platform for the development of novel therapeutics, 
particularly in the brain (Snyder et al. 1995).  We used recently developed techniques to 
reprogram somatic tissue into pluripotent cells with the rationale that patients would be less likely 
to mount a counter-productive immune response against autologous cells.  We decided that 
NSCs would be most appropriate for cell-based therapy in the brain based on previous studies 
demonstrating that NSC cell lines and primary NSCs can respond appropriately to developmental 
cues and migrate widely (Flax et al. 1998, Gage et al. 2013).  Importantly, immortalized NSCs 
have already proven to be effective following transplantation into neonatal and adult MPS VII 
mice (Snyder et al. 1995, Buchet et al. 2002). 
 We hypothesized that a comprehensive strategy, beginning with diseased MPS VII 
patient fibroblasts and ending with corrected patient NSCs, would effectively treat an 
immunodeficient mouse model of MPS VII.  To test this, we derived patient iPSCs from frozen 
fibroblasts using a modification of the Park et al. protocol (Park et al. 2008), omitting 2 of the 6 
reprogramming factors (hTERT and the SV40 large T antigen) to reduce the risk of tumogenesis.  
We then used a protocol previously shown to convert ESC/iPSCs into a stable long-term self-
renewing population of NSCs (Koch et al. 2009).  We reasoned that such a population of patient-
derived iPSC-NSCs would be ideal for expansion, genetic correction, and transplantation.  This 
combination of cellular reprogramming and genetic engineering techniques is a logical step 
towards developing personalized cell-based therapies in the brain.
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CHAPTER 2 
Genetically Corrected Neural Stem Cells 
Generated from MPS VII Patient Fibroblasts 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from Griffin TA, Anderson HC, and Wolfe JH.  Ex Vivo Gene Therapy 
Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse 
Model, Stem Cell Reports (Griffin et al. 2015).  
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I. Introduction  
Induced pluripotent stem cells are promising candidates for treating many diseases in the 
brain.  Unfortunately, disease-related mutations can impede this process.  It may not be possible 
to generate iPSCs from all patients, and differentiation towards therapeutic cell types can be 
impeded as well (Hamasaki et al. 2012, Ogawa et al. 2013).  It has been reported that iPSCs 
from mouse models of some LSDs (Sandhoff and MPS VII) are defective in their ability to 
differentiate towards neural lineages, which may severely hamper efforts to generate patient 
specific iPSC-derived NSCs suitable for transplantation (Meng et al. 2010, Ogawa et al. 2013).  
We hypothesized that β-glucuronidase (GUSB) deficiency should not be an obstacle to the 
reprogramming of MPS VII patient cells because of the cross-correction process.  Exogenous 
GUSB derived from the mouse embryonic feeder (MEF) layer upon which iPSCs are generated 
should serve as an adequate source of enzyme for deficient cells (Fratantoni et al. 1968).  
However, differentiation requires that iPSCs be removed from the MEF feeder layer, and it was 
unclear whether differentiation towards neural lineages would be impaired relative to control 
iPSCs. 
The current study demonstrates that fibroblasts from a female patient with MPS VII, 
frozen for ~30 years, can be reprogrammed through retroviral overexpression of Oct4, Sox2, Klf4, 
and c-Myc.  The GUSB mutations in these fibroblasts and consequent MPS VII phenotype has 
been extensively described elsewhere (Wu et al. 1994).  We show that these MPS VII iPSCs 
display stringent correlates of pluripotency including teratoma formation.  MPS VII iPSCs were 
successfully differentiated alongside control iPSCs into long-term self-renewing NSCs using a 
protocol developed for ESCs described previously (Koch et al. 2009).  Finally, a functional version 
of the GUSB gene was introduced into MPS VII iPSC-derived NSCs using a DNA transposon-
based vector (PiggyBac), demonstrating a comprehensive strategy that may be useful for 
generating clinically relevant transplantable NSCs in the future. 
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II. Results 
Generation and characterization of MPS VII iPSCs 
Frozen dermal fibroblasts from a patient with MPS VII (GM02784, Coriell Institute) were 
thawed, expanded, and transduced with VSV-G pseudotyped retroviral vectors expressing OCT4, 
SOX2, KLF-4, and c-MYC to initiate reprogramming.  This patient was previously reported to 
have 1.4% of normal β-glucuronidase activity in cultured fibroblasts (Wu et al. 1994).  Despite the 
fact that these fibroblasts had been frozen for ~30 years, colonies of ESC-like cells emerged 
alongside aggregates of partially reprogrammed cells, consistent with previous reports (Chan et 
al. 2009).  One line was selected for further characterization.   
To confirm the pluripotency of MPS VII iPSCs, standard in vitro and in vivo assays were 
performed. The putative MPS VII iPSC line displayed typical ESC/iPSC-like colony morphology 
(Fig. 2.1a) and expressed multiple markers of pluripotency including SSEA4, Tra-1-60, and Tra-
1-81 (Fig. 2.1b-d).  Cells injected into immunodeficient mice formed teratomas containing the 
three primary germ layers.  Hematoxylin and eosin stained teratoma sections revealed structures 
typical of endoderm, ectoderm, and mesoderm (Fig. 1e-h), and immunostained teratoma sections 
were positive for markers of each lineage (Fig. 2.1i-k).  iPSCs were passaged >40 times with no 
change in morphology or pluripotency marker expression.   
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Fig. 2.1 Generation of iPSCs from an MPS VII patient.  Fibroblasts from a female patient 
with MPS VII (GM02784) were transduced with retroviral vectors expressing the reprogramming 
factors Oct4, Sox2, Klf4, and c-Myc.  A putative iPSC line was isolated and expanded under 
serum-free conditions on a feeder layer of mouse embryonic fibroblasts.  MPS VII iPSC colonies, 
seen in the phase contrast image (a), expressed markers of pluripotency (b-d).  After injection 
into immunodeficient mice, MPS VII iPSCs formed teratomas (e) that differentiated into the three 
primary germ layers as shown by H&E stained sections (e-h) and germ layer specific marker 
expression (i-k).  α-FP = α-fetoprotein, SMA = smooth muscle actin, Tuj1 = βIII-tubulin, scale bars 
= 200µm (except in e).   
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Differentiation of MPS VII iPSC-NSCs 
 MPS VII and control iPSCs were passaged at least 20 times before being subjected to an 
adapted NSC differentiation protocol (Koch et al. 2009) (Fig. 2).  After iPSCs were removed from 
the MEF feeder layer and grown in suspension culture containing FBS, they formed large 
spherical aggregates. These “embryoid bodies” were plated and grown in a minimal neural 
induction medium.  A variety of cell types grew outward from the plated aggregates, including 
many with neurite-like extensions.  After approximately two weeks, neural tube-like structures 
began to form on some cell aggregates, consisting of a raised ring surrounding a central lumen 
(Elkabetz et al. 2008).  These rosette structures were isolated and grown as neurospheres for two 
days, after which they were dissociated and plated, yielding an adherent monolayer.  No obvious 
differences were observed between normal and MPS VII iPSCs during the differentiation 
procedure at any point and both yielded a relatively homogenous population of putative neural 
stem cells (Fig. 2.2). 
 
Characterization of MPS VII iPSC-NSCs 
The majority of the iPSC-NSCs (89.9 ± 2.9%) retained expression of the neural stem cell 
marker nestin (Fig. 3a). The rate of spontaneous differentiation into MAP2-positive neurons (9.5 ± 
0.8%) and GFAP-positive astrocytes (0.4 ± 0.6%) was low (Fig. 2.3a,b).   Importantly, no cells 
expressed the pluripotency marker Tra-1-60 or the reprogramming factor Oct4 (Fig. 2.3a,b).  The 
generation and culture of iPSCs from frozen MPS VII fibroblasts and the subsequent 
differentiation and propagation of iPSC-NSCs did not introduce any gross chromosomal 
abnormalities, as shown by a normal 46,XX karyotype (Fig. 2.3c).  To test the differentiation 
capacity of these cells, they were grown in terminal differentiation medium without growth factors 
for one month.  Differentiating conditions yielded neurons and astrocytes (Fig. 2.3d), as 
measured by MAP2 (86.4 ± 1.6%) and GFAP (13.9 ± 8.2%) expression, respectively (Fig. 2.3e).  
The majority of cells (74.8 ± 5.2%) were positive for the inhibitory neurotransmitter GABA, while 
there was no evidence of tyrosine hydroxylase-positive dopaminergic neurons (Fig. 2.3d,e). 
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Figure 2.2 Differentiation of NSCs from MPS VII and normal iPSCs.  Control and MPS VII iPSCs were removed from their MEF 
feeder layer and grown in suspension culture with FBS for five days to induce embryoid body formation.  The cell clusters were plated onto 
poly-ornithine coated dished and grown in neural induction media.  Neural tube-like structures (white arrows) began to appear and were 
manually isolated at day 20 and cultured in suspension in neurosphere media for two days.  Neurospheres were trypsinized and plated 
onto poly-ornithine/laminin coated dishes. Trypsinized cells were passaged as nestin-positive NSCs indefinitely.   
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Figure 2.3 Characterization and terminal differentiation of MPS VII iPSC-NSCs 
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Figure 2.3 Characterization and terminal differentiation of MPS VII iPSC-NSCs.  
(a,b) MPS VII NSC cultures expressed nestin (89.9 ± 1.5%) and showed low levels of 
spontaneous differentiation towards neurons (MAP2, 9.5 ± 0.4%) and astrocytes (GFAP, 0.4% ± 
0.3%).  No cells expressed the reprogramming factor Oct4 or the pluripotency marker Tra-1-60.  
(c) MPS VII iPSC-NSCs had a normal 46,XX karyotype.  (d,e)  NSCs were subjected to terminal 
differentiation by the removal of growth factors and the addition of cAMP for one month.  MAP2-
positive neurons comprised 86.4% ± 0.8% of all differentiated cells. The majority of those cells 
(74.8% ± 2.6%) were GABA-positive and none of the cells stained positive for the dopaminergic 
marker tyrosine hydroxylase (TH).  GFAP-positive astrocytes comprised 13.9% ± 4.1% of all 
differentiated cells.  Data are represented as the mean ± SEM, n=4 independent cultures.  Scale 
bars = 200µm 
 
Generation of GFP labeled and GUSB expressing MPS VII iPSCs 
 To introduce GFP into NSCs for the purpose of tracking their engraftment following 
transplantation, we first evaluated previously optimized transduction conditions using VSV-G 
pseudotyped lentiviral vector preps that had been extensively validated both in vitro and in vivo.  
Surprising, iPSC-derived NSCs proved exquisitely sensitive to lentiviral vectors.  Multiple 
attempts with different pseudotypes consistently resulted in cell death at MOIs >10 and were 
ineffective at transducing cells when the MOI < 10.  We therefore decided to switch to a PiggyBac 
transposon-based system consisting of 2 plasmids.  The first plasmid contains terminal repeats 
flanking two promoter units in tandem.  The 5’ promoter (CMV) drives expression of GUSB, 
followed by the EF1α promoter, which drives expression of both GFP and a puromycin resistance 
gene via a 2A polypeptide linker.  The second plasmid transiently expresses a transposase 
capable of integrating plasmid sequence bounded by terminal repeats into the genome at TTAA 
sites.  The use of a Lonza nucleofector and proprietary transfection reagents was very efficient at 
introducing vectors into iPSC-derived NSCs (fig..2.4a). However, when we placed a gene 
downstream of the CMV promoter (or CAG, switched to avoid promoter shutdown in the brain 
(Gray et al. 2011)), we observed very high levels of the transgene driven by the upstream 
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promoter, but expression of GFP and the puro resistance gene driven by EF1α was barely 
detectable. 
The iPSC-NSCs were electroporated with a PiggyBac vector containing GUSB cDNA 
driven by the CAG promoter.  A separate culture of the same passage of NSCs was prepared as 
a negative control by electroporating them with a mock-correction vector containing GUSB cDNA 
in the reverse orientation (revGUSB).  Following puromycin selection, mock-corrected MPS VII 
iPSC-NSCs had negligible GUSB activity (1.3 ± 1.3 nmol 4-MU/µg protein/ hr) while the corrected 
cells showed strong GUSB activity (116.8 ± 2.7 nmol 4-MU/µg protein/hr, p<0.01), comparable to 
an iPSC-NSC line derived from a healthy control (112.3 ± 3.1 nmol 4-MU/µg protein/hr, p >0.05) 
(Fig. 2d).   
To evaluate the issue of low expression from the downstream promoter, several 
transgenes or non-coding sequences were placed under the control of the upstream CAG 
promoter (GUSB, revGUSB, sialidase, EGFRVII, reprog), all of which had the same effect on 
GFP expression.  Expression of the puromycin resistance gene was good enough to select for 
transduced cells (fig. 2.4d) thanks in part to the sensitivity of iPSC-NSCs to puromycin, but no 
GFP could be visualized, even after immunohistochemistry for GFP protein.  We therefore used 
three populations of cells for future transplantation experiments: uncorrected/GFP-positive NSCs, 
corrected/GFP-negative NSCs, and mock-corrected/GFP-negative cells.  Further experiments 
using 293t cells demonstrated that replacing CAG with the minimal GUSB promoter results in 
much higher levels of GUSB as well as restoring strong expression of GFP and puromycin 
resistance from the EF1α promoter (fig. 2.5). 
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Figure 2.4 A PigyBac transposon vector efficiently introduces GFP or GUSB into 
MPS VII iPSC-derived NSCs.  (a) A PiggyBac transposon-based plasmid encoding GFP and 
a puromycin resistance gene was electroporated into MPS VII iPSC-NSCs.  (b) Puromycin was 
applied for 7 days in order to select for NSCs that had been stably transduced.  (c) MPS VII 
iPSC-NSCs retained their nestin expression and growth capacity after electroporation and 
puromycin selection.  (d)  Levels of β-glucuronidase expression in iPSC-derived NSCs from a 
normal control compared to MPS VII iPSC-derived NSCs receiving PiggyBac vector containing 
GUSB cDNA in the reverse orientation (mock-corrected) or GUSB in the forward orientation 
(corrected).  
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Figure 2.5 Effect of Promoter Choice on GUSB and GFP levels
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Figure 2.5 The Effect of Promoter Choice on GUSB and GFP levels.  The dual 
promoter PiggyBac system (Systems Biosciences) vector suffers from a major flaw.  When a 
coding sequence (or non-coding sequence [revGUSB]) (b,c) is inserted  into the multiple cloning 
site downstream of the CMV or CAG promoter, GFP expression from the EF1α promoter is 
severely reduced.  This is consistent with either promoter-shutdown or frank toxicity, both of 
which have been described previously (van den Pol et al. 1998, Papadakis et al. 2004).  (e)  Map 
of the dual expression plasmid vector.  (f) Transient transfection of 293t cells with 
PB.GUSB.GUSB shows improved GFP expression from the second promoter and much higher 
levels of GUSB expression.  PB.CAG.MCS = PiggyBac driven by the CAG promoter with nothing 
inserted into the multiple cloning site.  PB.CAG.GUSB = PiggyBac driven by the CAG promoter 
with GUSB cDNA inserted into the multiple cloning site.  PB.CMV.Reprog = PiggyBac driven by 
the CMV promoter with a quadrivalent set of reprogramming cDNAs inserted into the multiple 
cloning site.  PB.GUSB.GUSB = PiggyBac driven by the minimal GUSB promoter (~500 bp 
upstream of the start site) with GUSB cDNA inserted into the multiple cloning site. 
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III. Discussion 
First and foremost, these results demonstrate that a deficiency in GUSB does not 
preclude the generation of iPSCs or neural stem cells.  Given that deficient fibroblasts have 
access to exogenous enzyme from the MEF feeder layer during the reprogramming process, we 
predicted that GUSB deficiency would not be an obstacle to reprogramming.  It would have been 
preferable to use fresh patient cells, but the scarcity of MPS VII patient samples precluded this 
possibility.  Because our patient sample had been frozen so long ago, and given how extensively 
it has been utilized, it’s unclear how many divisions these cells have gone through.  Both of these 
factors (long-term freeze and high passage number) are known to reduce the efficiency of 
reprogramming.  As somatic cells divide, several factors decrease the efficiency of 
reprogramming, notably telomerase length (Huang et al. 2011).  We modified the iPSC 
generation protocol developed by Park et al. through the omission of the reprogramming factors 
telomerase (hTERT) and the SV40 large T antigen (Park et al. 2008). Potential consequences of 
including these factors include tumorigenesis and chromosomal instability (Ouellette et al. 2000, 
Ali et al. 2001).  Many groups have derived iPSCs without these factors, and we decided to omit 
them at the price of reprogramming efficiency.  
Subsequent to the generation of our MPS VII iPSCs, an article was published reporting 
the generation of iPSCs from three mouse models of LSD, including MPS VII (Meng et al. 2010).  
Of the LSDs examined, MPS VII iPSCs displayed defects in their differentiation capacity as 
measured by a significant decrease in the number and size of embryoid bodies generated when 
iPSCs were removed from their MEF feeder layer.  Exogenous application of recombinant β-
glucuronidase partially corrected this defect (Meng et al. 2010).  Another paper using a mouse 
model of the LSD Sandhoff disease showed specific defects in neural differentiation, raising 
further doubts about the ability to generate neural lineages from our human MPS VII iPSCs 
(Ogawa et al. 2013). 
In seeming contradiction to the Meng et al. study, when our MPS VII iPSCs were 
removed from the MEFs alongside control iPSCs, we saw no obvious differences in the ability to 
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generate neural lineages or long-term self-renewing NSCs.  Many factors could explain this 
discrepancy, including subtle differences in differentiation protocols, species-specific differences, 
or low levels of GUSB activity in the human iPSCs.  While undetectable using fluorometric 
methods in our lab, the patient fibroblasts were previously reported to express 1.4% normal levels 
of β-glucuronidase (Wu et al. 1994).  Human GUSB mutations resulting in the complete absence 
of β-glucuronidase activity usually result in pre-term or neonatal mortality (Vervoort et al. 1997, 
Vervoort et al. 1997, Tomatsu et al. 2009). In contrast, MPS VII mice can be viable in the 
complete absence of detectable β-glucuronidase activity, indicating the possibility of species-
specific differences (Sands et al. 1993).  Whatever the reason, our results clearly show that MPS 
VII patient fibroblasts can be reprogrammed.  Furthermore, they can be removed from all 
potential sources of exogenous enzyme, and differentiated into long-term self-renewing NSCs 
capable of generating mature neurons and glia. 
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CHAPTER 3 
MPS VII iPSC-Derived Neural Stem Cells Engraft Widely in Neonates 
and Correct Microglial Pathology in Adult MPS VII Mice 
        
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from Griffin TA, Anderson HC, and Wolfe JH.  Ex Vivo Gene Therapy 
Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse 
Model, Stem Cell Reports (Griffin et al. 2015).
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I. Introduction  
A combination of iPSC generation from easily accessible patient tissue, NSC 
differentiation protocols, ex vivo gene therapy, and transplantation directly back into the patient, 
may be an effective strategy for treating many LSDs.  In this chapter we transplant MPS VII iPSC-
derived NSCs into the brains of neonatal and adult mice with MPS VII.  To prevent immune 
rejection of human cells we used the immunodeficient NOD/SCID/MPS VII model previously 
described (Hofling et al. 2003).  GFP-labeled MPS VII iPSC-derived NSCs were transplanted in 
the ventricles of neonatal NOD/SCID and NOD/SCID/MPS VII littermates to evaluate the patterns 
and persistence of engraftment over the course of 4 months.  Corrected or mock-corrected MPS 
VII NSCs were also injected into the post-symptomatic striatum of 2 month old mice to evaluate 
the extent of disease correction.  We identified CD68-positive, activated microglia as an easily 
quantifiable biomarker of CNS pathology in these animals. This strategy permitted us to visualize 
engrafted cells and neuropathology in the same samples.  We further validated this method using 
an adeno-associated viral vector expressing β-glucuronidase in MPS VII mice.  
Following neonatal intraventricular transplantation, iPSC-NSCs engraft throughout the 
rostrocaudal axis of the CNS, primarily within white matter tracts, and survive for at least four 
months with little evidence of differentiation.  Genetically corrected and mock-corrected cells, 
while dispersed widely, were unable to correct microglial pathology.  Transplanted cells exited the 
cell-cycle rapidly and no differences were found between MPS VII and normal iPSC-NSCs 
engrafted in normal and MPS VII mice.  Genetically corrected MPS VII iPSC-NSCs transplanted 
post-symptomatically into the striatum of adult NOD/SCID/MPS VII mice reversed neuropathology 
in a zone surrounding the grafts, while control mock-corrected grafts did not.  MPS VII and control 
iPSC-NSCS did not migrate from the injection site, more consistent with data from primary NSCs 
than immortalized NSC lines.  The results suggest that improvements are needed to increase 
survival, enzyme expression levels, and migration, especially in adult animals. However, the 
dramatic amelioration of microglial pathology surrounding the corrected grafts provides a 
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compelling argument for ex vivo gene therapy in the brain using human NSCs from autologous, 
non-neural tissues.   
 
II. Results 
MPS VII patient iPSC-derived NSCs engraft widely in the neonatal brain 
To assess the engraftment potential of MPS VII iPSC-NSCs, GFP-labeled cells were 
injected intraventricularly into neonatal mice, which provide a more hospitable environment for 
engraftment relative to the adult brain (Snyder et al. 1995). Over 100 NOD-SCID neonates were 
injected with iPSC-NSCs between passages 15-25 with no evidence of deleterious effects in 
behavior or gross brain structure.  By 1 month post-transplant, cells had engrafted along the 
rostrocaudal axis of the brain and were primarily found in periventricular regions and white matter 
tracts (Fig. 3.1). Regardless of location, the engrafted cells expressed nestin and had an 
immature morphology (Fig. 3.1, lower panels).  GFP-labeled MPS VII iPSC-NSCs were also 
transplanted into NOD/SCID/MPS VII neonates.  At 4 weeks post-transplant the distribution of 
normal and MPS VII iPSC-NSCs engrafted cells was similar to the distribution in non-MPS VII 
NOD/SCID littermates, with cells found predominantly in the ventricles surrounding the 
hippocampi (Fig. 3.2). Thus the disease state of the mice did not alter the engraftment properties 
of donor cells. The iPSC-NSCs survived for at least four months (Fig. 3.3) with the donor cells 
predominantly located in the white matter at that time point.  Engrafted iPSC-NSCs remained in 
an immature stage even after four months in vivo, as indicated by human-specific nestin 
immunostaining (Fig. 3.3).  Interestingly, the same cells injected into the striatum of neonatal 
mice did reveal some evidence of differentiation to DCX-positive and β-III tubulin-positive 
neuronal cells (Fig. 3.4).  Despite their immature phenotype, transplanted iPSC-NSCs quickly 
exited the cell cycle.  At 1 week post-transplant, only a few cells expressed the cell proliferation 
marker Ki67 and no Ki67-positive cells were seen at 4 or 16 weeks post-transplant (Fig. 3.5).   
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Fig. 3.1 Distribution of Engrafted MPS VII iPSC-NSCs.  100,000 GFP-labeled iPSC-
NSCs were injected into the lateral ventricles of neonatal NOD/SCID mice.  (a) Diagram of the 
brain shows the relative rostral-caudal positions of the images below.  (b) One month post-
transplant, cells were found along the rostral-caudal axis of the brain, often adjacent to ventricles 
and within white matter tracts.  The areas within the white boxes are enlarged in the bottom 
panels, showing the morphology of engrafted iPSC-NSCs.  Scale bars = 500µm in upper panels 
of (b) and scale bar = 200µm in lower panels of (b). 
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Figure 3.2 Host Genotype does not Affect Neonatal Engraftment.                           
(a,b) Representative sections from two NOD/SCID animals transplanted with GFP labelled MPS 
VII iPSC-NSCs 4 weeks following neonatal transplantation.  (c,d) Similar sections from 2 
NOD/SCID/MPS VII animals.  Regardless of host genotype, transplanted cells are predominantly 
found in near ventricles, often surrounding the hippocampus.  Scale bar = 200µm. 
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Figure 3.3 MPS VII iPSC-NSCs survive and retain nestin expression four months following intraventricular injection.  
The presence of engrafted iPSC-NSCs was revealed by immunostaining four months after neonatal transplantation.  The highest 
concentrations were found in and along white matter tracts.  (a) Black boxes over Nissl stained coronal sections show the locations of 
engrafted MPS VII iPSC-NSCs seen below.  The location relative to bregma (in mm) is shown above each section.  (b) Engrafted MPS VII 
iPSC-NSCs remained nestin-positive even after four months in vivo. Scale bar = 200µm, cc = corpus callosum, vhc = ventral hippocampal 
commissure, opt = optic chiasm.  Nissl stained sections from the Allen Mouse Brain Atlas (Allen Institute for Brain Science).  
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Figure 3.4 Differentiation of MPS VII iPSC-derived NSCs in neonatal striatum.  
When uncorrected GFP-labeled cells were injected into the stratum of NOD/SCID mice, we saw 
very little migration after one month.  However, there was some evidence of differentiation.  DCX-
positive neuronal precursors with leading processes could be seen migrating away from the 
injection site (top row), while β-III tubulin-positive cells remained at the injection site (bottom 
row).  Mouse neurons are not seen in the background because the antibody binds much more 
strongly to human β-III tubulin.  This result shows that environmental signals play a role in 
determining the differentiation status of engrafted cells within the neonatal mouse brain. 
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Figure 3.5 MPS VII iPSC-NSCs Quickly Exit the Cell Cycle Following Neonatal 
Transplantation.  (a) MPS VII iPSC-NSCs in vitro prior to transplantation. The majority of cells 
stain positive for Ki67, a marker of cell division.  (b)  Vibratome section of NOD/SCID brain, one 
week following neonatal transplantation.  Very few transplanted cells were co-labeled with both 
human specific nuclei and Ki67.  (c,d)  No cells were found co-labeled with both human specific 
nuclei and Ki67 4 weeks or 16 weeks post-transplantation, indicating that transplanted cells are 
no longer dividing at these time points.  Scale bars = 200µm.
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Therapeutic potential of corrected MPS VII iPSC-NSCs  
MPS VII is a progressive disease with extensive pathology present by two months of age 
(Snyder et al. 1995, Levy et al. 1996).  Therefore, two-month-old NOD/SCID/MPS VII mice were 
injected bilaterally into the striatum with 50,000 corrected MPS VII iPSC-NSCs in one hemisphere 
and 50,000 mock-corrected cells in the contralateral hemisphere.  Animals were sacrificed one 
month later. Engrafted cells survived, remained nestin-positive, and did not migrate away from 
the injection site.  GUSB enzymatic activity, detected by a histochemical reaction (Snyder et al. 
1995) was limited to the injection site of the hemisphere receiving corrected cells (Fig. 3.6). 
To test whether the lack of differentiation and migration was unique to our MPS VII line or 
to the diseased environment, we transplanted iPSC-NSCs derived from a healthy human control, 
as well as MPS VII iPSC-NSCs, into NOD/SCID (non-MPS VII) adult mice.  At 1 month post-
transplant, engrafted cells from both lines remained at the injection site and stained positive for 
human-specific nestin (Fig. 3.7).  iPSC-NSCs from a normal and diseased source had the same 
properties when transplanted into adult brain parenchyma, demonstrating that the MPS VII iPSC-
NSC line used in our studies was not unique in this respect. 
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Figure 3.6 Corrected and Uncorrected MPS VII iPSC-NSCs Transplanted into Adult 
MPS VII Mouse Brain.  50,000 cells were injected bilaterally into the striatum of two month old 
NOD/SCID/MPS VII mice.  One hemisphere received corrected MPS VII iPSC-NSCs and the 
other hemisphere received mock-corrected MPS VII iPSC-NSCs.  One month following 
transplantation, enzyme activity was present at the injection tract in the hemisphere receiving 
corrected cells, but not in the hemisphere receiving mock-corrected cells. n=4 mice, scale bar = 
0.25mm.  
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Figure 3.7 MPS VII and Control iPSC-NSCs Transplanted into Adult Mouse 
Striatum.  (top row) Human specific nestin staining of sections from adult NOD/SCID mice one 
month post-transplantation with MPS VII iPSC-NSCs into adult striatum at two months of age (n = 
7 mice).  (bottom row) Human specific nestin staining of sections from adult NOD/SCID mice 
one month post-transplantation with iPSC-NSCs derived from a normal control (n = 5 mice).  
MPS VII and normal iPSC-NSCs remain at the injection site and stain positive for the NSC 
marker nestin.  Scale bar = 200µm. 
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Immunofluorescent Analysis of MPS VII animals at 3 Months of Age 
Given that MPS VII is a gradually progressive neurodegenerative disease, we evaluated 
a number of antibodies in frozen 20µm thick NOD/SCID/MPS VII brain sections at 3 and 8 
months of age to determine the best markers of pathology at 3 months, the age at which our 
experimental animals were sacrificed (Fig. 3.8).  We evaluated a number of markers known to be 
pathologically upregulated late in the disease process, but it was unknown to what extent these 
markers would be useful in 3 month old animals.  We examined lysosomal distention (LAMP2), 
astrogliosis (GFAP), secondary substrate accumulation (gangliosides GM2 and GM3), and a non-
specific fluorescent stain commonly used to mark degenerating neurons (Fluoro-Jade C) 
(Schmued et al. 2000).  We also evaluated the extent of microglial activation (via CD68 
immunostaining) as extensive microglial pathology has been reported in some, but not all LSDs 
(e.g. MPS IIIB, less so in MPS I) (Wada et al. 2000, Ohmi et al. 2003).  Neuro-inflammation is a 
common finding in MPS diseases (Archer et al. 2014), and microarray analysis of MPS VII brains 
from our lab showed that CD68, a major marker of microglial activation (Kreutzberg 1996), is 
transcribed at very high levels in the brain relative to normal mice (~10-fold higher across all brain 
regions) (Parente et al. 2012).  In fact, 25 of the top 36 genes upregulated relative to normal 
brains were associated with the manually curated “immune/inflammation” theme using DAVID 
functional annotation analysis (Huang da et al. 2009, Parente et al. 2012). We confirmed via 
immunostaining that CD68 was highly upregulated in NOD/SCID/MPS VII animals early in the 
disease process, preceding the appearance of other commonly used markers of neuropathology. 
CD68-positive microglia were uniformly distributed throughout the MPS VII brain by three months 
of age whereas CD68 was limited to small intracellular punctae within microglia of normal mice 
(Fig. 3.8 and 3.11d).  
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Figure 3.8 CD68-Positive Activated Microglia Precedes the Appearance of Other 
Markers of Neurodegeneration. NOD/SCID and NOD/SCID/MPS VII mice brain sections 
stained at three and eight months of age.  (a,b) Markers of neuropathology in three month-old 
mice and (c,d) eight month-old mice.  Lysosomal distension (LAMP2), secondary substrate 
accumulation (gangliosides GM2 and GM3), astrogliosis (GFAP), and neurodegeneration (Fluoro-
Jade C) occur after the appearance of CD68+ microglia.  LAMP2 = Lysosome-Associated 
Membrane Glycoprotein 2, GFAP = Glial Fibrillary Acidic Protein GM2 = GM2 ganglioside, GM3 = 
GM3 ganglioside.  Scale bar = 200µm.   
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Confirmation of CD68-Positive Microglia as a Marker of MPS VII Pathology  
To confirm that CD68 staining is a reliable marker for MPS VII neuropathology in 3 
month-old animals, we injected 2 month-old BL6/MPS VII mice bilaterally with an adeno-
associated viral vector encoding GFP (AAV1-GFP) in one hemisphere and a 1:1 mixture of 
AAV1-GFP and AAV1-GUSB in the other hemisphere (Fig. 3.9).  The total dose of vector was 
held constant at 1x1011.  We confirmed via immunostaining that CD68-positive microglia were 
already widespread by 2 months of age (data not shown).  The mice were sacrificed at three 
months and frozen sections were stained for enzyme activity and CD68.  The spherical nature of 
CD68-positive microglia combined with their relatively uniform distribution allowed us to develop a 
straightforward method of schematizing CD68 in whole brain sections.   
Using Photoshop to merge individual immunofluorescent images, combined with 
ImagePro software to identify and dilate all objects with an area greater than 20 pixels, we 
created schematics of CD68 that were easily amenable to quantification.  Adjacent sections were 
stained for enzyme activity using a sensitive colorimetric enzyme assay for the localization of β-
glucuronidase activity based on the cleavage of Naphthol AS-BI β-D-glucuronide and its 
subsequent reaction with a pararosaniline dye to create an insoluble product that is easily 
visualized (the HPR assay) (Wolfe et al. 1990, Gallagher 1992) (Fig. 3.9a).  Co-immunostaining 
of GFP and CD68 clearly shows a reduction in the number of CD68-positive cells surrounding the 
region that received the mixture of AAV1-GFP and AAV1-GUSB but not in the region receiving 
AAV1-GFP alone (Fig. 3.9b).  
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Figure 3.9 Absence of CD68-Positive Microglia Correlates with β-glucuronidase 
Activity in MPS VII animals.  MPS VII mice were injected with a mixture of AAV1-GFP and 
AAV1-GUSB in one hemisphere, while the contralateral hemisphere was injected with AAV2/1-
GFP alone (total of 1x1011 vector genomes, n=4 mice).  (A) A schematic of a CD68 
immunostained section shows a lack of CD68-positive microglia in the area surrounding the site 
injected with AAV1-GUSB one month post-injection.  (B) GFP and CD68 immunostaining shows 
a reduction in activated microglia surrounding the injection site of AAV1-GUSB + AAV1-GFP but 
not around the injection site of AAV1-GFP alone.  Scale bar = 200µm.  
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Evaluation of Pathology Following Neonatal Intraventricular Transplantation 
To determine if corrected or mock-corrected MPS VII iPSC-NSCs affected 
neuropathology in MPS VII mice, changes in activated microglia were used as a marker of 
neuropathology.  Three months following transplantation, engrafted cells could be found across 
the brain, but at low densities, similar to those seen following primary NSC grafts (Fig. 3.1 and 
3.3).  The HPR assay reveled cells clustered primarily in periventricular regions between the 
hippocampus and corpus callosum.  CD68-positive microglia were not reduced even in the 
regions directly adjacent to transplanted cells (Fig. 3.10). 
 
Evaluation of Pathology Following Adult Striatal Transplantation 
One month following adult transplantation, there was a striking reduction in CD68 
immunoreactivity surrounding the corrected MPS VII iPSC-NSC grafts, but not the mock-
corrected grafts (Fig. 3.11).  The density of CD68-positive cells was quantified in a 0.5 mm2 
region of interest (ROI) surrounding each injection tract (Fig. 11c).  There was a significant 
difference between the region surrounding corrected grafts (49.2 ± 9.9 cells/mm2) and the region 
surrounding mock-corrected grafts (145.2 ± 13.2 cells/mm2, p<0.0001) (Fig. 3.11c).  There was 
not a significant difference between the region surrounding mock-corrected grafts and a 
comparable region of untreated MPS VII striatum (166.1 ± 13.4 cells/mm2, p>0.05).  
Immunostaining for CD68 and the pan-microglial marker Iba1 showed that the microglia in 
untreated MPS VII mice as well as the microglia surrounding mock-corrected iPSC-NSCs had a 
distended, amoeboid-type morphology (Fig. 3.11d).  The region surrounding corrected iPSC-
NSCs contained smaller, ramified-type microglia, which closely resembled the microglia in normal 
control brains (Fig. 3.11d).  
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Figure 3.10 Low Levels of Engraftment Following Neonatal Transplantation do not 
Reduce CD68-positive Microglia
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Figure 3.10 Low Levels of Engraftment Following Neonatal Transplantation do not 
Reduce CD68-positive Microglia.   NOD/SCID/MPS VII neonates and their non-MPS VII 
littermates were injected intraventricularly with 50,000 corrected MPS VII patient iPSC-derived 
NSCs or PBS.  The sensitivity of the HPR assay (left column) allowed for the detection of sub-
therapeutic levels of levels of β-glucuronidase activity in engrafted cells (red stained areas).  
CD68-positive cells were widespread in mice receiving PBS or corrected iPSC-derived NSCs, 
even in areas directly adjacent to corrected cells (right column).  Normal littermates showed no 
signs of CD68-positive microglia at this suddestin, Anlaysins of.   
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Figure 3.11 Correction of Microglial Pathology Following Adult iPSC-derived NSC 
Transplantation.   
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Figure 3.11 Correction of Microglial Pathology Following Adult iPSC-derived NSC 
Transplantation. Corrected and mock-corrected iPSC-NSCs (50,000 cells/condition) were 
injected intrastriatally into the right and left hemisphere respectively, of adult NOD/SCID/MPS VII 
mice.  (a)  Schematic of a representative coronal section showing engrafted MPS VII iPSC-NSCs 
and CD68-positive microglia one month post-transplantation. (b) Immunofluorescent images of 
nestin-positive iPSC-NSCs at the site of injection. The region surrounding the corrected MPS VII 
iPSC-NSCs contained significantly fewer activated microglia than in the region surrounding mock-
corrected MPS VII iPSC-NSCs or in a comparable region of untreated MPS VII striatum.  CD68-
positive microglia with an area greater than 20 pixels was quantified (c).  (d) Confocal images of 
Iba1 and CD68 immunoreactivity in resident microglia. The brains of MPS VII mice showed 
marked microglial activation, as evident by upregulated CD68 expression and amoeboid 
morphology.  Microglia adjacent to corrected, but not mock-corrected, MPS VII iPSC-NSCs 
exhibited a ramified morphology and low CD68 expression typical of the quiescent microglia 
found in normal mice.  Mean ± SEM, n=3 sections/mouse, n=4 mice, scale bar = 200µm in (b) 
and 30µm in (d).   
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III. Discussion 
 In Chapter 2 we showed that MPS VII patient-derived iPSCs can be differentiated into 
long-term self-renewing NSCs, similar to iPSCs from an unaffected control.  In order to evaluate 
the engraftment potential of these cells we transplanted them within the ventricles and striatum of 
neonatal NOD/SCID mice.  We then tested the therapeutic potential of these cells by quantifying 
microglial pathology surrounding corrected and mock-corrected grafts in MPS VII mice.  
Cells transplanted intraventricularly into neonatal mice survived and engrafted throughout 
white matter tracts in the brain.  However, they remained nestin-positive even 4 months post-
transplantation.  In contrast, Koch et al. found mature engrafted neurons at the same time point 
following neonatal telencephalic injections using similar ESC-derived NSCs (Koch et al. 2009).  
We ruled out the possibility that reactivation of the retroviral transgenes was responsible for the 
lack of differentiation by co-immunostaining using antibodies against human nuclei and Oct4. Our 
experiments primarily utilized intraventricular injections to maximize the spread of engraftment, 
and we hypothesized that the site of injection might explain the lack of differentiation.  We found 
that injecting cells into the striatum of neonatal mice resulted in some neuronal differentiation one 
month post-transplantation.  In contrast to the cells found in the white matter after intraventricular 
injection, we found DCX-positive neuronal precursors and β-III tubulin-positive neurons with an 
immature morphology near the injection site.  The engrafted cells failed to migrate far from the 
striatal injection site.  This is consistent with previous studies showing that the location of 
engraftment makes a difference in the differentiation and migration potential of transplanted 
NSCs (Watson et al. 2006).   
The mouse sub-ventricular zone (SVZ) provides a niche for stem cells in the mouse 
brain, and this may serve to inhibit NSC differentiation (Ghashghaei et al. 2007).  Autoattraction 
of transplanted cells likely plays a role in the lack of migration.  The same group that first 
demonstrated the ESC to NSC protocol used in the Koch et al. study Iater published a report 
demonstrating that NSCs transplanted onto live brain slices failed to migrate (Ladewig et al. 
2014).  They used cells expressing GFP under the control of the DCX promoter to distinguish 
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between NSCs and neural progenitor cells (NPCs).  After sorting DCX-positive cells they 
transplanted a pure population of NPCs and found that they migrated very well.  They 
demonstrated that blockade of VEGF and FGF2 receptors on the surface of neural progenitor 
cells (NPCs) allowed for greater migration in the presence of NSCs.  This was accomplished 
using antibodies against VEGF and FGF2 receptors or a tyrosine kinase inhibitor, nintedanib 
(Ladewig et al. 2014). This is consistent with our results and the results of other studies showing 
that chemoattractant signaling plays a large role in NSC migration.  NSCs are known to migrate 
towards areas of injury, such as tumors or even the needle track created during the surgical 
procedure (Aboody et al. 2000, Boockvar et al. 2005).  Chemokines such as PDGF and stromal 
cell-derived factor 1α (SDF-1α, or CXCL12) are likely to play a role in attracting NSCs expressing 
CXC chemokine receptor 4 (CXCR4) (Imitola et al. 2004, Ladewig et al. 2014). 
One week following neonatal transplantation, cells were found primarily within and 
adjacent to ventricles. After one month, cells were widely distributed throughout white matter 
tracts.  This is consistent with many studies showing that NSCs from various sources display a 
tropism for white matter in both normal and pathological contexts (Tabar et al. 2005, Maciaczyk et 
al. 2009, Carney et al. 2011, Gupta et al. 2012).  This affinity for white-matter tracts may be useful 
for treating leukodystrophies or as a pathway for NSC dissemination. The limited migration of 
transplanted NSCs within grey matter may be a barrier to widespread delivery for some diseases 
with global CNS pathology; however, axonal transport can facilitate wider distribution of 
lysosomal proteins within this group of diseases (Passini et al. 2002). 
Another factor limiting engraftment is donor cells exiting the cell-cycle.  While iPSC-NSCs 
grew prolifically in culture, they stopped dividing shortly after transplantation.  Very few Ki67-
positive cells were found one week post-transplantation and no Ki67-positive cells were found at 
one or four moths post-transplantation. Ideally, a population capable of limited or controlled cell 
division will strike the delicate balance between total engraftment levels and the risk of 
tumorigenesis. 
Due to the intrinsic variation between ESC and iPSC lines, we were concerned that the 
results we found following transplantation were specific to our MPS VII iPSC line.  As a control, 
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we transplanted an iPSC line derived by an independent source (the CHOP iPSC core) using a 
different reprogramming method (Cre-excisable constitutive polycistronic lentivirus) (Sommer et 
al. 2010). Based on the similar behavior of the lines, we concluded that the results were not an 
artifact of our particular line. 
A major hurdle we overcame was the evaluation of pathology in treated brains at 3 
months-of-age. Neuropathology of MPS VII is often evaluated in very thin sections (0.5-5µm), 
necessitating that brains be embedded in plastic (e.g. JB4), epoxy (e.g. Epon), or paraffin (Heuer 
et al. 2002, Liu et al. 2005, Mikula et al. 2012).  We opted to use thicker (~20µm) frozen sections 
to evaluate pathology for several reasons: 1) The antibodies used in these studies were validated 
and optimized using frozen sections 2) paraffin, plastic, or epoxy sectioning of so many brains 
(>100) was impractical, and 3) The use of plastic or epoxy sections generally precludes IHC, 
reducing our ability to co-localize engrafted cells and pathology (Shi et al. 1991, McCluggage et 
al. 1995, Cai et al. 2005). 
We systematically evaluated antibodies validated in older animals in addition to 
antibodies against candidate proteins identified by microarray.  We found that only CD68 was 
highly upregulated in MPS VII animals at 3 months of age, and therefore decided to use this as 
our primary readout of pathology. 
Neonatally engrafted cells migrated widely, and could be visualized immunofluorescently 
using antibodies against GFP, human nuclei, and human-specific nestin.  They could also be 
visualized using the highly sensitive HPR assay.  Unfortunately, there was no difference in CD68-
positive microglia, even directly surrounding the transplanted cells.  In contrast, our adult 
transplantation experiments unambiguously show that a high local concentration of corrected 
MPS VII iPSC-NSCs cleared CD68-positive microglia in an area surrounding the graft.  Ramified 
microglia in the corrected region had small soma and extended processes, consistent with a 
quiescent microglial state (Kreutzberg 1996).  
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CHAPTER 4 
Conclusions and Future Directions 
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Figure 4.1 Graphical Outline of an iPSC-derived NSC-based Strategy for β-
glucuronidase Replacement in the Brain using a Xenograft Model of MPS VII.     
The general use of this strategy involves removing somatic cells from the patient, reprogramming 
them via introduction of the transcription factors Oct4, Sox2, Kl4, and c-MYC.  Using 
differentiation protocols developed for ESCs/iPSCs, pluripotent cells can be converted to long-
term self-renewing neural stem cells.  Introduction of the GUSB gene via DNA transposon-
mediated (PiggyBac) gene delivery rescues the mutant phenotype in cells.  Following 
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transplantation in the brain, β-glucuronidase is secreted by corrected cells and taken up by 
nearby affected cells, thereby reducing pathology in vivo. 
I.  Conclusions 
Here we demonstrate the feasibility of ex vivo gene therapy for the treatment of 
neuropathology accompanying metabolic disease using patient-derived somatic cells from a 
readily accessible source (e.g. frozen skin biopsy).  By reprogramming patient fibroblasts into 
pluripotent stem cells and subsequently generating genetically corrected tissue-specific stem 
cells, we evaluated a therapeutic strategy that can be applied to many genetic diseases affecting 
the brain. We show, via xenotransplantation into a mouse homologue of the human disease, that 
such a strategy can reverse pathologic lesions surrounding engrafted cells.   
The success of NSC-based therapy will depend on protocols that yield well-characterized 
and expandable lines suitable for transplantation. We chose an NSC differentiation protocol for its 
ability to generate a self-renewing population of relatively homogenous NSCs from ESC and 
iPSC lines (Koch et al. 2009, Falk et al. 2012). The in vitro characteristics of MPS VII iPSC-NSCs 
generated here were consistent with reports utilizing similar ESC-based protocols in regards to 
the immunophenotype and ability to generate predominately GABAergic neurons upon withdrawal 
of growth factors (Koch et al. 2009).   
We found that GUSB deficiency did not compromise the ability of human MPS VII iPSCs 
to generate embryoid bodies or differentiate towards neural lineages, in contrast to a previous 
report on mouse MPS VII iPSC lines (Meng et al. 2010).  Disease-related phenotypes have been 
reported, in vitro, in iPSCs derived from patients with other LSDs such as Niemann-Pick type C or 
MPS IIIB (Lemonnier et al. 2011, Bergamin et al. 2013), and in primary canine MPS VII NSCs 
(Walton et al. 2007).  However, there was no evidence in our study that the MPS VII iPSC-NSCs 
or their progeny had a disease-related phenotypic difference in vitro. We directly compared 
corrected and mock corrected NSCs by immunofluorescent analyses and found no significant 
differences.  We also co-cultured corrected or mock-corrected iPSC-NSCs with primary cortical 
cells derived from MPS VII or normal littermate controls (data not shown).  After loading the co-
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cultures with a calcium dependent fluorescent dye, we were able to visualize several network 
properties in real time (Patel et al. 2015). While these experiments were preliminary, we found no 
differences in network firing properties between corrected iPSC-NSC/MPS VII cortical co-cultures 
and mock-corrected iPSC-NSC/control cortical co-cultures. Furthermore, the GUSB deficiency did 
not impair engraftment as we observed no apparent differences in the number or distribution of 
genetically corrected and mock-corrected MPS VII iPSC-NSCs following transplantation into MPS 
VII mice.  More GUSB-negative cell lines are needed to determine if this phenomenon is specific 
to our MPS VII line or merely reflects the subtlety of the disease. 
 Transplantation of iPSC-NSCs within the neonatal brain yielded stable engraftment 
across the neuroaxis for at least four months, but only within and adjacent to white matter tracts. 
Although the precise mechanisms are unclear, NSCs from various sources display a tropism for 
white matter in both normal and pathological contexts (Tabar et al. 2005, Maciaczyk et al. 2009, 
Carney et al. 2011, Gupta et al. 2012).  The affinity for white-matter tracts may be useful for 
treating leukodystrophies and as a pathway for NSC dissemination.  The limited migration of 
transplanted NSCs within grey matter precludes widespread delivery for some diseases with 
global CNS pathology, however axonal transport can facilitate wider distribution of lysosomal 
proteins within this group of diseases (Passini et al. 2002).   
 We transplanted iPSC-NSCs into neonatal mice in order to evaluate their behavior in a 
more appropriate developmental context.  Many of the cues required for survival and migration of 
NSCs are present in neonates but not in healthy adults (Guzman et al. 2007).  We found that 
iPSC-NSCs engrafted widely but sparsely, which is consistent with neonatal transplants of 
primary mouse NSCs (Chaubey et al. 2013).  Following transplantation directly into grey matter 
(adult striatum), the iPSC-NSCs remained localized to the injection tract.  As a consequence, 
microglial pathology was corrected in a zone surrounding the graft, corresponding to the 
distribution of enzyme in three dimensions in the brain parenchyma (Taylor et al. 1997).  In 
contrast, neonatal transplants engrafted throughout the white matter but were too sparse to 
significantly reduce the number of CD68-positive cells, even in regions directly adjacent to 
corrected cells.  Thus, substantial improvements to increase both the density and distribution of 
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donor cells within the brain will be needed to deliver the therapeutic enzyme to more areas of the 
brain to advance clinically relevant NSC therapy further for LSDs.   
The engrafted iPSC-NSCs showed very little evidence of differentiation, even four 
months post-transplant.  The absence of mature neurons and glia following neonatal and adult 
transplantation stands in contrast to the efficient differentiation of iPSC-NSCs in vitro.  This result 
underscores the need for a better understanding of the environmental signals governing NSC 
differentiation.  However, for use in correcting most LSDs the differentiation status of engrafted 
cells is not critical, provided that they do not cause deleterious effects in the brain.  
Undifferentiated cells may in fact be advantageous, as inappropriate neurotransmitter release 
from mature engrafted neurons can be harmful in some settings.  One example of this is the graft-
induced dyskinesias resulting from cell replacement therapy in Parkinson’s disease patients 
(Lane et al. 2010). 
 Gene and cell based therapies that successfully deliver lysosomal enzymes in the brain 
reduce pathology in many animal models of LSD (Simonato et al. 2013).  To test whether 
genetically corrected patient iPSC-NSCs could deliver corrective levels of GUSB, we evaluated 
pathology in the adult striatum surrounding the graft.  We assayed disease-associated 
neuroinflammation as a biomarker, using CD68-positive activated microglia.  Evidence for a 
microglial contribution to MPS VII pathology was previously shown via microarray analysis of 
normal and diseased brains (Parente et al. 2012).  Microglial involvement has been well 
documented in some, but not all, storage diseases including MPS IIIB and Sandhoff disease 
(Wada et al. 2000, Ohmi et al. 2003), and activated CD68-positive microglia have been used as a 
biomarker for correction of pathology (Lee et al. 2007). We show here that microglial activation is 
a significant and early component of MPS VII neuropathology.  CD68-positive microglia are 
particularly useful as a quantifiable biomarker of MPS VII neuropathology because of their 
distended size, spherical morphology, and uniform distribution.   
 We observed no differences in the engraftment capacity of corrected and mock-corrected 
MPS VII iPSC-NSCs. Activated microglia adjacent to mock-corrected grafts appeared distended 
and amoeboid, indistinguishable from microglia in comparable regions of the untreated MPS VII 
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brain. In contrast, the area surrounding corrected grafts contained significantly fewer CD68-
positive cells.  The microglia were reduced in size and adopted a more ramified-type morphology 
consistent with the phenotype of resting microglia seen in normal animals.   
 Mock-corrected grafts did not provide any therapeutic benefit, suggesting that GUSB 
alone was responsible for correcting neuropathology, rather than anti-inflammatory or other 
factors expressed by the iPSC-NSCs themselves.  The observation that GUSB over-expression 
from an AAV vector similarly reduces CD68-positive microglia corroborates the conclusion that 
GUSB activity is solely responsible for the correction of neuropathology.   
The spatially restricted nature of correction following cell transplantation indicates the 
need for new differentiation protocols or other strategies capable of increasing NSC migration 
within the brain parenchyma.  Overall, our results suggest that a comprehensive strategy 
involving somatic reprogramming and gene therapy could benefit patients with neuropathology 
from storage diseases affecting the brain. 
 
II. Issues Related to Measuring Neuropathology in MPS VII mice. 
 The amount of storage present in 3 month-old MPS VII animals proved insufficient to 
reliably distinguish from controls. The presence of storage lesions at this time point has been 
established via electron microscopy (Levy et al. 1996) and immunostaining of poly-ubiquitin 
inclusions in paraffin sections (Heuer et al. 2002).  However, the limited distribution of our grafts 
combined with the small percentage of NOD/SCID/MPS VII offspring from heterozygous breeding 
pairs made these strategies impractical on a scale needed to adequately power our studies.  Our 
original plan was to stain frozen cryosections with antibodies that had been validated on 8 month-
old animals. However, there was very little difference between 3 month-old normal and mutant 
mice using these antibodies, including the same poly-ubiquitin antibody used previously on 
paraffin embedded sections of 3 month-old mice.  Standard immunoflourescent detection of 
pathology becomes problematic as autofluorescent material accumulates over time in mutant 
animals.  By 8 months-of age there is extensive autofluorescent material accumulated throughout 
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the brain, preventing all but the best antibodies from discriminating between real signal and 
autofluorescence.  Of all the antibodies we tested using cryosections of 3 month-old 
NOD/SCID/MPS VII brains, α-CD68 clearly stood out.  The pan-microglial markers Iba1 and 
CD11b confirmed that microglial activation precedes other hallmarks of pathology.  The spherical, 
uniformly distributed nature of activated microglia in the MPS VII brain made it possible to 
develop an automated method of identifying and quantifying these cells in the areas surrounding 
the iPSC-NSC grafts.  Given that activated microglia are known to be present at an early age in 
many lysosomal storage diseases, we hope that this simple method of software-based 
quantitative fluorescent image analysis may prove useful for the field.  Importantly, this activation 
is not strain-specific, and is readily detectible in both NOD/SCID/MPSVII and BL6/MPS VII by 2 
months of age, the earliest time point examined.   
 
III. Future Aims 
 By genetically correcting MPS VII iPSCs at the NSC stage we limited ourselves to using 
only these cells for all transplantation experiments.  Genetically manipulating cells at the iPSC 
stage would allow us to test multiple differentiation protocols.  To this end, we modified the iPSC 
culture conditions allowing us to transfect cells and select stably transfected iPSCs with improved 
versions of our PiggyBac vectors that contain the GUSB promoter (Fig. 4.2).  Another concern is 
line-to-line variability among individual ESC and iPSC lines.  Given that there is always some 
level of variability in terms of gene expression and differentiation potential, it is desirable to 
generate more MPS VII lines.  Given the rarity of the disease, and the fact that we had to derive 
our MPS VII iPSC line from frozen fibroblast samples (a very inefficient process), it may not be 
worth the time and effort to derive more lines directly from patient samples.  
The use of recently developed gene editing technologies (e.g. TALEN and CRISPR) may 
be a more attractive option for generating GUSB-deficient pluripotent cell lines (Christian et al. 
2010, Ran et al. 2013).  Knocking out GUSB in well-established ESC lines such as H9 (Amit et al. 
2000) or iPSC lines provides several advantages.  Most MPS VII patients have some small but 
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residual expression of β-glucuronidase, and eliminating all enzymatic activity may yield additional 
insights into the function of the enzyme and the pathophysiology of disease.  Another advantage 
to using well established lines is that we can mitigate the effect of line-to-line variability inherent to 
pluripotent stem cell lines.  Our current plan is to knock out GUSB in the normal iPSC line used in 
these studies as well as in the well-studied H9 ESC line.  CRISPR guide RNAs have been 
created and transfected into a normal iPSC line, and clones are currently undergoing genotyping 
and enzymatic analysis to confirm that no β-glucuronidase is present.  Multiple GUSB-/- ESC and 
iPSCs lines compared to their parental GUSB+/+ lines would provide further evidence that patient-
specific iPSC-NSCs (or other progenitor cell types) can be a safe and effective therapy for LSDs 
in the brain. 
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Figure 4.2 Genetically Corrected and Mock-Corrected MPS VII Patient iPSC labeled 
with GFP.  MPS VII iPSCs were dissociated into single cells and transfected with one of two 
optimized PiggyBac transposon vectors described previously (Fig. 2.5).  The use of the GUSB 
promoter (rather than CMV or CAG) resulted in much higher β-glucuronidase levels in 293t cells 
while maintaining GFP expression from the downstream EF1α promoter.  Transfecting and 
plating iPSCs on a high concentration of Matrigel in the presence of the ROCK inhibitor Y-27632 
resulted in many colonies surviving, a small percentage of which were GFP positive. Several 
clones from each condition were isolated and expanded. Correction of patient iPSCs allows for 
the evaluation of multiple differentiation methods to increase survival and migration following 
transplantation. 
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IV. Future CNS Cell Therapy 
 The studies undertaken here, combined with results from many other groups, 
demonstrate that the exact method of deriving NSCs, the source, the age of transplantation, the 
transplantation site, and the pathological state of the host brain can dramatically alter the fate of 
transplanted NSCs (Snyder et al. 1992, Snyder et al. 1995, Taylor et al. 1997, Boockvar et al. 
2005, Tabar et al. 2005, Corti et al. 2008, Koch et al. 2009, Maciaczyk et al. 2009, Chaubey et al. 
2013, Jensen et al. 2013, Mazzini et al. 2015).  Our data suggest that early-stage NSCs may not 
be ideal for widespread cell therapy in the brain.  Several promising pluripotent stem cell-derived 
alternatives have been recently developed that deserve to be more thoroughly evaluated in a 
therapeutic context.  
 One approach involves the migratory progeny of long-term self-renewing NSCs similar to 
the iPSC-NSCs used in our experiments.  After initiating the differentiation process, Laedewing et 
al. showed that DCX-positive neuroblasts, derived from non-migratory NSCs, migrated 
extensively in slice culture (Ladewig et al. 2014).  Another ESC-derived cell type shown to 
migrate widely in the brain has been generated by mimicking the developmental cues 
encountered by cells in the medial ganglionic eminence (MGE).  The MGE is a subcortical 
structure adjacent to the embryonic lateral ventricles.  It is the birthplace of most cortical 
interneurons, which must migrate long distances before functionally integrating into cortical 
circuits (Wonders et al. 2006).  Highly migratory MGE-like cells derived from human ESC/iPSCs 
can be selected based on their expression of the transcription factor NKX2.1 (Maroof et al. 2013).  
A drawback of these approaches is the requirement of fluorescent reporters to purify the cell-type 
of interest from a heterogeneous population.  Refinements to differentiation protocols or the 
identification of cell surface markers will be required before these cell types can be used clinically.               
  Currently, one of the most promising approaches to achieving widespread CNS 
engraftment involves glial progenitor cells (GPCs) rather than NSCs.  GPCs, also known as 
oligodendrocyte precursor cells or NG2+ glia, comprise the majority of mitotic cells in the adult 
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human brain and as much as 5-10% of total cells, depending on the region (Dimou et al. 2015).  
In adults, GPCs are primarily responsible for generating oligodendrocytes for the purpose of 
mylenating axons, but are capable of differentiating into astrocytes and even neurons (Rivers et 
al. 2008, Sim et al. 2009).  GPCs can be purified from primary human tissue using surface 
markers including NG2, A2B5, and PDGFRA (Goldman et al. 2012).  They can also be generated 
in vitro from ESC/iPSCs or via direct reprogramming (Wang et al. 2013, Yang et al. 2013).   
Human GPCs, whether derived from primary tissue or pluripotent cells, have the rather 
amazing quality of actively displacing murine glia following adult transplantation (Windrem et al. 
2014).  Over the course of a year, transplanted human GPCs migrated throughout the white 
matter and gradually advanced into the cortex, eliminating endogenous glia and supplanting their 
function.  Furthermore, engrafted mice demonstrated increased synaptic plasticity and performed 
better on several cognitive tasks.  Relative to mice engrafted with murine GPCs and unengrafted 
mice, animals engrafted with human cells showed enhanced long-term potentiation (LTP), maze 
performance, fear conditioning, and object-location memory (Han et al. 2013).  Engrafted glia 
were morphologically and functionally human, and unknown species-specific factors conferred a 
clear competitive advantage.  When the mechanism/s responsible are elucidated, it may be 
possible to alter GPCs in vitro, giving the cells a similar advantage in an autologous host. 
Microglia are major effectors of catabolism in the brain, and their correction or 
replacement could restore a critical scavenger function in storage disease patients.  With the 
hope that bone marrow-derived stem cells would replace microglia and other macrophages while 
providing a plentiful source of enzyme for the body, bone marrow transplantation (BMT) has been 
performed on ~1000 LSD patients with generally disappointing results (Rovelli 2008).  With the 
exception of very young pre-symptomatic patients, BMT is usually not worth the significant risks.  
Relative to other LSDs, BMT has been most successful in treating MPS I, and trials have shown 
modest results for treating Krabbe disease and metachromatic leukodystrophy (Escolar et al. 
2005, Biffi et al. 2013, Aldenhoven et al. 2015).  A more thorough understanding of the factors 
governing success and failure will facilitate the development of more effective cell therapies 
targeting the brain.   
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  One important variable is the enzyme’s effective therapeutic dose.  In the case of MPS 
I, just 0.4% of normal catalytic activity can be enough to confer a relatively mild phenotype, 
partially explaining the efficacy of BMT for this disease (Bunge et al. 1998).  It’s important to 
maximize the amount of enzyme produced by each engrafted cell.   Take for example the recent 
ex vivo gene therapy trial for metachromatic leukodystrophy (MLD) (Biffi et al. 2013).  Lentiviral 
overexpression of arylsulfatase A in conjunction with autologous BMT was very effective in 
preventing disease, at least in a small group of pre-symptomatic patients.   
Microglia and other tissue resident macrophages can self-renew, and they are not 
normally replaced by cells from the bone marrow.  In order to get significant numbers of bone 
marrow-derived cells into the brain a niche must first be created.  After killing resident myeloid 
precursors in the brain with radiation or chemotherapy, bone marrow-derived cells entered the 
brain and differentiated into microglia (Capotondo et al. 2012).  This effect was seen with 
busulfan, which crosses the blood-brain-barrier, but not with theosulfan, which does not 
(Capotondo et al. 2012).  Clinical trials that reported enzyme activity in the brain almost all used 
busulfan as the primary chemotherapeutic (Rovelli 2008).   PLX3397 is an inhibitor of the CSF-1 
receptor (CSF1R) and it has the remarkable ability to kill all resident microglia over the course of 
a few weeks. This compound was recently used to show that long-term microglial depletion in 
adults has very little effect on behavior and that the microglial repopulating cells are likely 
perivascular cells that transiently express nestin (Elmore et al. 2014).  PLX3397 or similar drugs 
may be important for creating a niche in which blood-borne donor cells have a real competitive 
advantage in the brain.  
The exact source of cells greatly influences the outcome as well.  Umbilical cord stem 
cells actually engrafted better than peripheral blood stem cells and bone marrow-derived stem 
cells for MPS I (Boelens et al. 2007).  iPSC-derived microglial precursors may be an ideal source 
of enzyme in the brain capable of being delivered IV.  Under the right conditions, it’s plausible that 
myeloid progenitors could even replace resident macrophages throughout the body.  A microglial 
differentiation protocol has already been established for murine pluripotent stem cells, and should 
be relatively straightforward to adapt it for human cells (Beutner et al. 2010).  The success of cell 
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transplantation for LSDs will depend on advances in differentiation techniques and transplantation 
biology, which in turn rely on a broad understanding of the origins and behavior of cells in both 
normal and pathological circumstances.  
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Materials and Methods 
Generation of MPS VII iPSCs 
Frozen fibroblasts were obtained from a 3 month old female patient (GM02784, Coriell Institute 
for Medical Research) with no detectable β-glucuronidase activity.  Fibroblasts were maintained 
in DMEM containing 15% FBS.  Reprogramming was performed as previously described with 
some modifications (Park et al. 2008).  Retroviral vectors expressing Oct4, Sox2, Klf4, and c-Myc 
were produced in 293t cells using the pMXs backbone (courtesy of Dr. Shinya Yamanaka, 
Addgene plasmids 13366, 13367, 13375, and 17219) and pseudotyped with VSV-G (Takahashi 
et al. 2006).  MPS VII fibroblasts were transduced with the reprogramming vectors and after five 
days were split onto mitomycin-C inactivated mouse embryonic fibroblasts (MEFs).  The cells 
were maintained in iPSC media containing ROCK inhibitor Y-27632 (10µM, Sigma) until colonies 
were ready to be picked.  Putative iPSC colonies were manually picked and transferred to fresh 
MEFs.  Subsequently, iPSC cultures were passaged either manually or enzymatically with 
dispase (Gibco).  Control iPSCs were obtained from the ESC/iPSC core of the Children’s Hospital 
of Philadelphia, and generated using the Cre-excisable STEMCAA lentiviral vector (Sommer et al. 
2010).   
Teratoma formation 
MPS VII iPSCs (1x106) were resuspended in 140µL DMEM/F12 and mixed with 60µL Matrigel 
(BD biosciences). The cell suspension was injected subcutaneously in NOD/SCID mice (Jackson 
Labs).  Teratomas were removed 6 weeks later and either frozen for immunostaining or 
embedded in paraffin for H&E staining.  
Differentiation and culture of NSCs 
MPS VII and control iPSCs were differentiated based on a protocol for generating long-term self-
renewing NSCs from ESCs (Koch et al. 2009).  Briefly, iPSC colonies were removed from the 
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MEF feeder layer and 20% FBS was added in order to generate embryoid bodies.  At day five the 
embryoid bodies were attached to poly-ornithine (Sigma) coated dishes and switched to a 
minimal neural induction media containing insulin, transferrin, selenium, and fibronectin (Sigma) 
until neural tube-like structures appear.  At day 20 these tube-like structures were manually 
removed from the surrounding cell mass using a dissecting microscope and transferred to a 
suspension culture containing N-2 supplement (1:100, Gibco), bFGF (10 ng/mL, Gibco), and EGF 
(10 ng/mL, Sigma).  Cells were trypsinized at day 23 and plated on poly-ornithine/laminin (BD 
biosciences) coated plates in NSC media containing bFGF (10ng\mL), EGF (10ng\mL), insulin 
(20µg/mL, Gibco), N-2 (1:100), and B-27 (1:1000, Gibco).  iPSC-NSCs were passaged 1:2 every 
three to four days by trypsinization.  
Characterization of iPSC-NSCs 
G-banded karyotyping of iPSC-NSCs (p9) was performed by Cell Line Genetics.  Terminal in vitro 
differentiation was carried out in Neurobasal:DMEM/F12 (Gibco) containing N-2 (1:100), B-27 
(1:100), and cyclic AMP (300ng/mL, Sigma) for one month.  Quantification of the percentage of 
undifferentiated and terminally differentiated iPSC-NSCs expressing cell-type specific markers 
was performed by manual counting of immunofluorescently labeled slides.  Percentages are 
represented as means ± S.E.M. (n=4).  
Gene transfer in MPS VII iPSC-NSCs 
GFP labeling of iPSC-NSCs was achieved using a PiggyBac expression vector containing a 
puromycin resistance gene (PB-513B-1, Systems Biosciences).  The CMV promoter sequence 
was replaced with the CAG promoter sequence using SpeI and EcoRI.  GUSB was cloned into 
the PiggyBac plasmid using SmaI sites flanking the GUSB cDNA and a SwaI site within the 
multiple cloning site of the PiggyBac plasmid.  Blunt-end ligation produced a correction vector as 
well a mock-correction vector containing GUSB in the reverse orientation.  For transfection of 
iPSC-NSCs, we used the Lonza Kit for Mouse Neural Stem Cells according to the manufacturer 
instructions. 4x106 cells were electroporated with 3µg of the GUSB expression vector or GFP 
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control + 1µg of the transposase expression plasmid (PB200PA-1, Systems Biosciences) using 
the Lonza Nucleofector set to program A-33. After allowing the cells a few days to recover, 
transfected cells were selected with 0.5µg/mL puromycin for one week.  
Neonatal NSC Transplantation 
Neonatal NOD/SCID mice were cryoanesthetized prior to transplantation.  iPSC-NSCs were 
trypsinized and resuspended in PBS at 50,000 cells/µL.  2µL of the cell suspension was injected 
into each lateral ventricle using a pulled glass micropipette.  All procedures were approved by the 
Institutional Care and Use Committee at the Children's Hospital of Philadelphia.   
Adult NSC Transplantation 
Prior to injection, 8 week old NOD/SCID or NOD/SCID/MPS VII mice (breeding stock was a kind 
gift of Drs. M. Sands and J. Nolta) were anesthetized with isofluorane and secured in a sterotaxic 
frame (Kopf).  Burr holes were drilled into the skull and 50,000 corrected or mock-corrected cells 
in 1µL PBS were infused at a rate of 0.5µl/minute. The striatal coordinates were: 0.50mm caudal 
to bregma, 1.5mm left or right of midline, and 3.0mm ventral to the dural surface.  
Adult AAV Injection 
Prior to injection, 8 week old C57BL/6/MPS VII mice (n=4) were anesthetized with isofluorane 
and secured in a sterotaxic frame (Kopf).  Burr holes were drilled into the skull and AAV2/1 vector 
in 1µL of PBS was infused at a rate of 0.5µl/minute. One hemisphere was injected with AAV2/1-
GFP, and the contralateral hemisphere was injected with a 1:1 mixture of AAV2/1-GFP and 
AAV2/1-GUSB (total of 1X1011 vector genomes).   Packaging, purification, and tittering were 
performed by The University of Pennsylvania Vector Core as previously described (Passini et al. 
2003) The coordinates used for injection were: 0.50mm rostral to bregma, 1.5mm left or right of 
midline, and 3.0mm ventral to the dural surface.  
Immunostaining 
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Brains were embedded in 2% agarose prior to vibratome sectioning and immunostaining.  60µm 
coronal sections were stored in PBS + 0.1% Na azide at 4º until ready for use.    Brains were 
cryoprotected with 30% sucrose prior to embedding in OCT (Tissue-Tek).  20µm-thick frozen 
sections were cut using a cryostat (Leica).  Vibratome and frozen sections were post-fixed in 4% 
paraformaldehyde and permeabilized in 0.3% Triton X-100.  After blocking in 4% goat serum, the 
sections were incubated in primary antibody containing 1% serum for 1 hour at RT.  Antibodies 
used and their concentrations are listed in Supplemental Table 1.  Images were acquired using 
an epifluorescence microscope (DM6000 B, Leica) or a confocal-scanning laser microscope 
(FluoView1000, Olympus).   
Image analysis and statistics 
To visualize the distribution of CD68-positive microglia in MPS VII mice following adult iPSC-NSC 
engraftment, a montage of immunofluorescent images was combined using the photomerge tool 
in Photoshop CS6 (Adobe).  ImagePro Plus 3.0 (Media Cybernetics) was used to identify and 
dilate all objects with an area greater than 20 pixels.  CD68-positive microglia were quantified 
within 0.25mm of engrafted iPSC-NSCs. The density of microglia adjacent to corrected and 
mock-corrected cells was compared by two-tailed t-test using Prism 5.0 (Graphpad).  Microglia 
with a CD68-positive area greater than 20 pixels were counted.  Frozen sections (20µm) were 
quantitated for each condition, and data are represented as means ± S.E.M. (n=7).  
β-glucuronidase assays 
Napthol-AS-BI-β-D-glucuronide was used to determine the presence of GUSB activity in 20µm 
thick frozen sections as previously described (Snyder et al. 1995).  For quantitation of β-
glucuronidase activity in MPS VII and control NSCs, the fluorescence of hydrolyzed 4-
methylumbelliferyl-β-D-glucuronide was measured as previously described (Cervera 2005).  
Three independent cultures were quantified, and data are represented as means ± S.E.M.  
Gene transfer in iPSCs 
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MPS VII and normal iPSCs, normally passaged using dispase, were dissociated into single cells 
using TrpLE in the presence of 10µm Y-27632.  The cells were plated on mitomycin-C inactivated 
MEFs which were in turn plated on a 1:3 dilution of Matrigel.  X-tremeGENE 9 (Roche) was used 
to introduce PiggyBac (GUSB or revGUSB) and transposase plasmids 24 hr after iPSCs had 
been plated.  After one week, green colonies were picked and expanded. 
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Figure 5.1 List of Antibodies used the Study 
 
Antibody Vendor Catalog number Concentration 
mouse anti-SSEA4 Millipore MAB4304 1:100 
mouse anti-Tra-1-60 Millipore MAB4360 1:100 
mouse anti-Tra-1-81 Millipore MAB4381 1:100 
mouse anti-human specific nestin Millipore MAB5326 1:250 
mouse anti-human specific nuclei Millipore MAB1281 1:200 
goat anti-DCX Santa Cruz sc8066 1:100 
mouse anti-β-III tubulin Neuromics MO15013 1:1000 
mouse anti-MAP2 Sigma M4403 1:500 
rabbit anti-GABA Sigma A2052 1:1000 
rabbit anti-GFAP Millipore AB5804 1:1000 
mouse anti-Tyrosine hydroxylase Sigma T1299 1:1000 
rabbit anti-KI67 Leica NCL-ki67p 1:200 
rabbit anti-S100β Immunostar 22520 no dilution 
mouse anti-Oct4 Abcam Ab18976 1:100 
mouse anti-c-Myc Sigma C3956 1:500 
mouse anti-O4 Millipore MAB345 1:100 
rabbit anti-Iba1 Wako 019-19741 1:1000 
rat anti-CD68 Abd Serotech MCA1957 1:200 
rabbit anti-α-Fetoprotein Abcam ab9372 1:100 
mouse anti-Smooth muscle actin Santa Cruz sc-53142 1:200 
goat anti-mouse Alexafluor 488 or 594 Life Technologies A-11001/A11005 1:250 
goat anti-rat Alexafluor 594 Life Technologies A-11007 1:250 
donkey anti-goat Alexafluor 594 Life Technologies A-11058 1:250 
goat anti-rabbit Alexafluor 488 or 594 Life Technologies A-11008/A-11012 1:250 
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